,Unnamed: 0,Unnamed: 0.1,Drug,Chemical Structure,Adverse Effect / Toxicity,Species,Dose,Dose Type,Route,Source,Source Link,Year
0,0,0,Abacavir Sulfate,NC1=NC(NC2CC2)=C2N=CN(C3C=CC(CO)C3)C2=N1,Hepatomegaly,Rat,-2.7748361825616668,Repeated,Oral,"FDA approval package document: Pharmacology Review 020977/S-000; 020978/S-000 Part 01, page:21 PDF 1163k",https://www.pharmapendium.com/browse/fda/Abacavir Sulfate/07c4f5b0213d6bee80ea94c6175056dd?reference=21,1998.0
1,1,17,Abiraterone Acetate,CC(=O)OC1CCC2(C)C(=CCC3C2CCC2(C)C(C4=CN=CC=C4)=CCC32)C1,Hepatomegaly,Rat,-2.439332693830263,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/542871/2011; EMEA/H/C/002321, page:21 PDF 1612k",https://www.pharmapendium.com/browse/ema/Abiraterone Acetate/185740296add1ce30dc73add0801259d?reference=21,2011.0
2,2,19,Acetaminophen,CC(=O)NC1=CC=C(O)C=C1,Hepatomegaly,Rat,-1.3979400086720375,Repeated,Intravenous,"FDA approval package document: Pharmacology Review 204767/S-000, page:57 PDF 19675k",https://www.pharmapendium.com/browse/fda/Acetaminophen/ad96944ddec8bfde10b95a4fae87c443?reference=57,2012.0
3,3,22,Aclidinium Bromide,O=C(OC1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)C(O)(C1=CC=CS1)C1=CC=CS1,Hepatomegaly,Mouse,-7.146128066699271,Repeated,Inhalation,"FDA approval package document: Pharmacology Review 202450/S-000 Part 06, page:70 PDF 15689k",https://www.pharmapendium.com/browse/fda/Aclidinium Bromide/b314c7c42e68103349050f55e75f335c?reference=70,2011.0
4,4,26,Adapalene,COC1=CC=C(C2=CC3=CC=C(C(=O)O)C=C3C=C2)C=C1C12CC3CC(CC(C3)C1)C2,Hepatomegaly,Rat,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Pharmacology Review 020380/S-010, page:12 PDF 1438k",https://www.pharmapendium.com/browse/fda/Adapalene/cdfa46929ca03ebfa90ed9644754496e?reference=12,2016.0
5,5,27,Afamelanotide,CCCCC(NC(=O)C(CO)NC(=O)C(CC1=CC=C(O)C=C1)NC(=O)C(CO)NC(C)=O)C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC=N1)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(CCCN=C(N)N)C(=O)NC(CC1=CNC2=C1C=CC=C2)C(=O)NCC(=O)NC(CCCCN)C(=O)N1CCCC1C(=O)NC(C(N)=O)C(C)C,Hepatomegaly,Rat,-1.3010299956639813,Repeated,Subcutaneous,"EMA approval document: Assessment Report, page:31 PDF 4573k",https://www.pharmapendium.com/browse/ema/Afamelanotide/8ef0e37be16327e672af77a41df452b1?reference=31,2014.0
6,6,29,Agomelatine,COC1=CC2=C(CCNC(C)=O)C=CC=C2C=C1,Hepatomegaly,Rat,-2.096910013008056,Repeated,Oral,"EMA approval document: Scientific Discussion EMEA/655251/2008, page:11 PDF 992k",https://www.pharmapendium.com/browse/ema/Agomelatine/27e42ced3422d3adb8be6432b6d01dbf?reference=11,2008.0
7,7,36,Albendazole,CCCSC1=CC2=C(C=C1)NC(NC(=O)OC)=N2,Hepatomegaly,Rat,-1.975431808509263,Repeated,Oral,"FDA approval package document: Pharmacology Review 020666, page:26 PDF 1532k",https://www.pharmapendium.com/browse/fda/Albendazole/96e83f5037b99b0fd1462dbaae95a5a5?reference=26,1996.0
8,8,40,Albuterol Sulfate,CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1,Hepatomegaly,Rat,-8.036096449259214,Repeated,Inhalation,"FDA approval package document: Approval Package 019269/S-014; 019773/S-008 Part 01, page:15 PDF 3541k",https://www.pharmapendium.com/browse/fda/Albuterol Sulfate/8be963703d698f72b854283a96a91e2c?reference=15,1987.0
9,10,44,Alectinib Hydrochloride,CCC1=CC2=C(C=C1N1CCC(N3CCOCC3)CC1)C(C)(C)C1=C(C2=O)C2=C(C=C(C#N)C=C2)N1,Hepatomegaly,Rat,-0.4771212547196624,Repeated,Oral,"FDA approval package document: Pharmacology Review 208434/S-000, page:147 PDF 18427k",https://www.pharmapendium.com/browse/fda/Alectinib Hydrochloride/58836d69022270b42fe1db46093ae15f?reference=147,2015.0
10,11,45,Alfuzosin Hydrochloride,COC1=CC2=NC(N(C)CCCNC(=O)C3CCCO3)=NC(N)=C2C=C1OC,Hepatomegaly,Rat,-2.292256071356476,Repeated,Oral,"FDA approval package document: Pharmacology Review 021287/S-000 Part 01, page:24 PDF 1318k",https://www.pharmapendium.com/browse/fda/Alfuzosin Hydrochloride/e0725d4b1356803a41d34119e5da56f6?reference=24,2003.0
11,12,51,Almotriptan Malate,CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2,Hepatomegaly,Rat,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Pharmacology Review 021001/S-000 Part 01, page:54 PDF 1950k",https://www.pharmapendium.com/browse/fda/Almotriptan Malate/65a4fd1f91a6b2d9de68e8285c53b339?reference=54,1997.0
12,13,52,Alogliptin Benzoate,CN1C(=O)C=C(N2CCCC(N)C2)N(CC2=C(C#N)C=CC=C2)C1=O,Hepatomegaly,Rat,-2.837053981681968,Repeated,Oral,"FDA approval package document: Pharmacology Review 022271/S-000; 022426 Part 05, page:36 PDF 5127k",https://www.pharmapendium.com/browse/fda/Alogliptin Benzoate/629b0b6453156e05c41174d542c6f0f4?reference=36,2012.0
13,14,66,Alosetron Hydrochloride,CC1=C(CN2CCC3=C(C2=O)C2=C(C=CC=C2)N3C)N=CN1,Hepatomegaly,Rat,-1.6434526764861874,Repeated,Oral,"FDA approval package document: Pharmacology Review 021107/S-000 Part 03, page:8 PDF 688k",https://www.pharmapendium.com/browse/fda/Alosetron Hydrochloride/97c2cc8990641a87289d61470bd2d96a?reference=8,1999.0
14,15,73,Ambrisentan,COC(C1=CC=CC=C1)(C1=CC=CC=C1)C(OC1=NC(C)=CC(C)=N1)C(=O)O,Hepatomegaly,Rat,-2.687974620034556,Repeated,Oral,"FDA approval package document: Pharmacology Review 022081/S-000 Part 02, page:90 PDF 7551k",https://www.pharmapendium.com/browse/fda/Ambrisentan/c4ae62a66fc4f48dc8750a821739f110?reference=90,2003.0
15,17,81,Amdinocillin,CC1(C)SC2C(/N=C/N3CCCCCC3)C(=O)N2C1C(=O)O,Hepatomegaly,Rat,-2.066946789630613,Repeated,Subcutaneous,"FDA approval package document: Approval Package 050565 Part 01, page:8 PDF 4997k",https://www.pharmapendium.com/browse/fda/Amdinocillin/98282e407fde0d44e23549f4f9c934e1?reference=8,1983.0
16,18,84,Amifampridine,NC1=CC=NC=C1N,Hepatomegaly,Rat,-0.4771212547196624,Repeated,Oral,"EMA approval document: Assessment Report EMEA/H/C/001032, page:17 PDF 531k",https://www.pharmapendium.com/browse/ema/Amifampridine/ecc29ff280b769afc3c94bc2e06da635?reference=17,2009.0
17,19,85,Amifampridine Phosphate,NC1=C(N)C=NC=C1,Hepatomegaly,Rat,-1.3010299956639813,Repeated,Oral,"FDA approval package document: Pharmacology Review 208078/S-000 Part 02, page:84 PDF 11391k",https://www.pharmapendium.com/browse/fda/Amifampridine Phosphate/6971567a1cf6dab94b9c91505aaac1a6?reference=84,2018.0
18,20,91,Aminolevulinic Acid Hydrochloride,NCC(=O)CCC(=O)O,Hepatomegaly,Rat,-2.0,Repeated,Oral,"FDA approval package document: Pharmacology Review 208630/S-000, page:18 PDF 3615k",https://www.pharmapendium.com/browse/fda/Aminolevulinic Acid Hydrochloride/640039e288fff44a7e49927777ce7f64?reference=18,2017.0
19,21,93,Aminophylline,CN1C(=O)C2=C(N=CN2)N(C)C1=O,Hepatomegaly,Rat,-1.0791812460476249,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Toxicology and Applied Pharmacology 7,291,1965   ---   DOI:10.1016/0041-008X(65)90097-9   ISSN:0041-008X   JOURNAL:Toxicology and Applied Pharmacology   PAGES:291   VOLUME:7",http://dx.doi.org/10.1016/0041-008X(65)90097-9,1965.0
20,22,94,Amiodarone Hydrochloride,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=CC=CC=C2O1,Hepatomegaly,Rat,-1.4393326938302626,Repeated,Oral,"FDA approval package document: Approval Package 018972/S-000 Part 01, page:8 PDF 1509k",https://www.pharmapendium.com/browse/fda/Amiodarone Hydrochloride/1ffebdb6bf4deba0d2bd2efdcc52ccd4?reference=8,1988.0
21,23,96,Amitriptyline Hydrochloride,CN(C)CCC=C1C2=C(C=CC=C2)CCC2=C1C=CC=C2,Hepatomegaly,Rat,-0.9542425094393248,Repeated,Intragastric,Reference from PharmaPendium Published Toxicity: 2005119040   ---   DOI:10.1016/j.toxlet.2020.02.007   ISSN:0378-4274   JOURNAL:Toxicology Letters   PAGES:43   VOLUME:325,http://dx.doi.org/10.1016/j.toxlet.2020.02.007,2020.0
22,25,98,Amoxicillin,CC1(C)SC2C(NC(=O)C(N)C3=CC=C(O)C=C3)C(=O)N2C1C(=O)O,Hepatomegaly,Rat,-3.3010299956639813,Repeated,Oral,"FDA approval package document: Pharmacology Review 050813/S-000, page:15 PDF 1634k",https://www.pharmapendium.com/browse/fda/Amoxicillin/015eb266cdcc47e3a5cc7bdec962f77d?reference=15,2007.0
23,26,99,Amphotericin B,CC1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/C(OC2OC(C)C(O)C(N)C2O)CC2OC(O)(CC(O)CC(O)C(O)CCC(O)CC(O)CC(=O)OC(C)C(C)C1O)CC(O)C2C(=O)O,Hepatomegaly,Rat,-1.0,Repeated,Intravenous,"FDA approval package document: Approval Package 050724 Part 02, page:61 PDF 5905k",https://www.pharmapendium.com/browse/fda/Amphotericin B/a0fb7f56d6dd1ca570987dce7397b902?reference=61,1995.0
24,28,101,Amprenavir,CC(C)CN(CC(O)C(CC1=CC=CC=C1)NC(=O)OC1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1,Hepatomegaly,Rat,-2.544068044350276,Repeated,Oral,"FDA approval package document: Pharmacology Review 021007/S-000; 021039/S-000, page:19 PDF 1550k",https://www.pharmapendium.com/browse/fda/Amprenavir/48f67e7468197a28681d5099ab1d2aae?reference=19,1998.0
25,29,107,Anastrozole,CC(C)(C#N)C1=CC(C(C)(C)C#N)=CC(CN2C=NC=N2)=C1,Hepatomegaly,Rat,-1.3979400086720375,Repeated,Oral,"FDA approval package document: Pharmacology Review 020541/S-010, page:13 PDF 829k",https://www.pharmapendium.com/browse/fda/Anastrozole/6bc1d39cbdef73502c2b202a1539bdac?reference=13,2002.0
26,30,109,Anidulafungin,CCCCCOC1=CC=C(C2=CC=C(C3=CC=C(C(=O)NC4CC(O)C(O)NC(=O)C5C(O)C(C)CN5C(=O)C(C(C)O)NC(=O)C(C(O)C(O)C5=CC=C(O)C=C5)NC(=O)C5CC(O)CN5C(=O)C(C(C)O)NC4=O)C=C3)C=C2)C=C1,Hepatomegaly,Rat,-1.5440680443502757,Repeated,Intravenous,"FDA approval package document: Pharmacology Review 021948/S-000; 021632/S-000, page:29 PDF 3419k",https://www.pharmapendium.com/browse/fda/Anidulafungin/5a8b3f5b87ca9a0caf47f2e7024cc485?reference=29,2003.0
27,32,112,Apremilast,CCOC1=C(OC)C=CC(C(CS(C)(=O)=O)N2C(=O)C3=CC=CC(NC(C)=O)=C3C2=O)=C1,Hepatomegaly,Mouse,-2.8750612633917,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/476353/2014; EMEA/H/C/003746, page:41 PDF 5634k",https://www.pharmapendium.com/browse/ema/Apremilast/5d252b41c66ed82190c08c6fb94cc716?reference=41,2014.0
28,36,175,Atazanavir Sulfate,COC(=O)NC(C(=O)NC(CC1=CC=CC=C1)C(O)CN(CC1=CC=C(C2=NC=CC=C2)C=C1)NC(=O)C(NC(=O)OC)C(C)(C)C)C(C)(C)C,Hepatomegaly,Rat,-2.780557320149522,Repeated,Oral,"EMA approval document: Scientific Discussion, page:9 PDF 362k",https://www.pharmapendium.com/browse/ema/Atazanavir Sulfate/a93a11d3afbe70add1b85a41351c4441?reference=9,2004.0
29,37,181,Atomoxetine Hydrochloride,CNCCC(OC1=CC=CC=C1C)C1=CC=CC=C1,Hepatomegaly,Rat,-1.293730756922482,Repeated,Oral,"FDA approval package document: Pharmacology Review 021411/S-000 Part 05, page:23 PDF 1497k",https://www.pharmapendium.com/browse/fda/Atomoxetine Hydrochloride/add15c7e5acb04911dbe2878416de97d?reference=23,2001.0
30,41,203,Aztreonam,CC1C(=NC(=O)C(NOC(C)(C)C(=O)O)C2=CSC(N)=N2)C(=O)N1S(=O)(=O)O,Hepatomegaly,Rat,-2.617000341120899,Repeated,Subcutaneous,"FDA approval package document: Approval Package 050580 Part 04, page:47 PDF 6472k",https://www.pharmapendium.com/browse/fda/Aztreonam/7b921af7cebff9f1cb6a52238d057819?reference=47,1986.0
31,45,224,Bempedoic Acid,CC(C)(CCCCCC(O)CCCCCC(C)(C)C(=O)O)C(=O)O,Hepatomegaly,Rat,-1.5637776333621658,Repeated,Oral,"FDA approval package document: Approval Package 211616/S-000 Part 08, page:1 PDF 849k",https://www.pharmapendium.com/browse/fda/Bempedoic Acid/ab62f621ee1b630854d8da3ece6dda69?reference=1,2019.0
32,47,240,Benznidazole,O=C(CN1C=CN=C1[N+](=O)[O-])NCC1=CC=CC=C1,Hepatomegaly,Rat,-1.0,Repeated,Oral,"FDA approval package document: Pharmacology Review 209570/S-000 Part 01, page:49 PDF 11345k",https://www.pharmapendium.com/browse/fda/Benznidazole/ea6c524b79d1ed8cd262a8adc8124792?reference=49,2017.0
33,48,241,Benzophenone,O=C(C1=CC=CC=C1)C1=CC=CC=C1,Hepatomegaly,Rat,-1.4471580313422192,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Food and Chemical Toxicology 29,741,1971   ---   DOI:10.1016/0278-6915(91)90182-7   ISSN:0278-6915   JOURNAL:Food and Chemical Toxicology   PAGES:741   VOLUME:29",http://dx.doi.org/10.1016/0278-6915(91)90182-7,1971.0
34,49,242,Benzydamine,CN(C)CCCOC1=NN(CC2=CC=CC=C2)C2=C1C=CC=C2,Hepatomegaly,Mouse,-1.146128035678238,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Toxicology and Applied Pharmacology 10,148,1967   ---   DOI:10.1016/0041-008X(67)90136-6   ISSN:0041-008X   JOURNAL:Toxicology and Applied Pharmacology   PAGES:148   VOLUME:10",http://dx.doi.org/10.1016/0041-008X(67)90136-6,1967.0
35,51,259,Bepridil Hydrochloride,CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1,Hepatomegaly,Mouse,-2.397940008672037,Repeated,Oral,"FDA approval package document: Approval Package 019002 Part 07, page:1 PDF 2218k",https://www.pharmapendium.com/browse/fda/Bepridil Hydrochloride/5da4edd69312579909a910644baac7a0?reference=1,1990.0
36,54,265,Betaxolol Hydrochloride,CC(C)NCC(O)COC1=CC=C(CCOCC2CC2)C=C1,Hepatomegaly,Rat,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Approval Package 019270/S-000, page:51 PDF 4585k",https://www.pharmapendium.com/browse/fda/Betaxolol Hydrochloride/3fe68fe535613daf2fd91b3bbf70919e?reference=51,1985.0
37,56,268,Bexarotene,C=C(C1=CC=C(C(=O)O)C=C1)C1=C(C)C=C2C(=C1)C(C)(C)CCC2(C)C,Hepatomegaly,Rat,-1.59659709562646,Repeated,Oral,"FDA approval package document: Pharmacology Review 021055/S-000 Part 01, page:19 PDF 1153k",https://www.pharmapendium.com/browse/fda/Bexarotene/3b5738f6e24512f5e7d2e26086bd425d?reference=19,1999.0
38,58,284,Bivalirudin,CCC(C)C(NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(CC(=O)O)NC(=O)CNC(=O)C(CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(N)CC1=CC=CC=C1)C(=O)N1CCCC1C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=C(O)C=C1)C(=O)NC(CC(C)C)C(=O)O,Hepatomegaly,Rat,-2.397940008672037,Repeated,Intravenous,"FDA approval package document: Pharmacology Review 020873/S-000 Part 03, page:6 PDF 1408k",https://www.pharmapendium.com/browse/fda/Bivalirudin/41f60d987acb34b425c6a4e8b8f69a46?reference=6,1999.0
39,60,288,Bosentan,COC1=CC=CC=C1OC1=C(OCCO)N=C(C2=NC=CC=N2)N=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1,Hepatomegaly,Rat,-3.0301441417228645,Repeated,Oral,"FDA approval package document: Pharmacology Review 021290/S-000 Part 01, page:10 PDF 1496k",https://www.pharmapendium.com/browse/fda/Bosentan/fb952a4c87173b3d2b6aa2e23b6753ac?reference=10,2001.0
40,61,296,Bremelanotide Acetate,CCCCC(NC(C)=O)C(=O)NC1CC(=O)NCCCCC(C(=O)O)NC(=O)C(CC2=CNC3=C2C=CC=C3)NC(=O)C(CCCN=C(N)N)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC2=CNC=N2)NC1=O,Hepatomegaly,Mouse,-1.7520484478194385,Repeated,Subcutaneous,"FDA approval package document: Approval Package 210557/S-000 Part 08, page:30 PDF 10057k",https://www.pharmapendium.com/browse/fda/Bremelanotide Acetate/02d5935322778cb32696d30da098b4b2?reference=30,2018.0
41,62,300,Brinzolamide,CCNC1CN(CCCOC)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2,Hepatomegaly,Rat,-2.255272505103306,Repeated,Oral,"FDA approval package document: Pharmacology Review 020816/S-000 Part 01, page:35 PDF 1222k",https://www.pharmapendium.com/browse/fda/Brinzolamide/ec687d600c7fb731237cddf608dec88b?reference=35,1997.0
42,63,302,Brivaracetam,CCCC1CC(=O)N(C(CC)C(N)=O)C1,Hepatomegaly,Rat,-2.583576585633949,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/822086/2015; EMEA/H/C/003898/0000, page:28 PDF 1391k",https://www.pharmapendium.com/browse/ema/Brivaracetam/b57268d9ac3068c5cc834f5adc6fd0ba?reference=28,2015.0
43,65,306,Budesonide,CCCC1OC2CC3C4CC=C5CC(=O)C=CC5(C)C4C(O)CC3(C)C2(C(=O)CO)O1,Hepatomegaly,Rat,-6.778151250383644,Repeated,Inhalation,"FDA approval package document: Pharmacology Review 020746/S-000, page:14 PDF 982k",https://www.pharmapendium.com/browse/fda/Budesonide/4f1fb593e80bd51d06988d9e9b4c42a6?reference=14,1998.0
44,66,307,Bumetanide,CCCCNC1=CC(C(=O)O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1,Hepatomegaly,Rat,-1.4259687322722812,Repeated,Oral,"FDA approval package document: Approval Package 018225; 018226 Part 01, page:19 PDF 5382k",https://www.pharmapendium.com/browse/fda/Bumetanide/baf0fae035aea232184bc6d48ef45834?reference=19,1994.0
45,68,335,Butenafine Hydrochloride,CN(CC1=CC=C(C(C)(C)C)C=C1)CC1=CC=CC2=CC=CC=C12,Hepatomegaly,Rat,-2.2587056809417,Repeated,Subcutaneous,"FDA approval package document: Pharmacology Review 020524/S-005, page:6 PDF 399k",https://www.pharmapendium.com/browse/fda/Butenafine Hydrochloride/46b97c5aea2bd9e60954934697394239?reference=6,2000.0
46,70,345,Caffeine Citrate,CN1C(=O)C2=C(N=CN2C)N(C)C1=O,Hepatomegaly,Rat,-1.8129133566428557,Repeated,Intragastric,"FDA approval package document: Pharmacology Review 020793/S-000, page:27 PDF 2833k",https://www.pharmapendium.com/browse/fda/Caffeine Citrate/7fa4b021e6153510d5650dd90c1dce9a?reference=27,1999.0
47,71,348,Calcitriol,C=C1/C(=C\C=C2/CCCC3(C)C2CCC3C(C)CCCC(C)(C)O)CC(O)CC1O,Hepatomegaly,Rat,-7.176091259055681,Repeated,Intravenous,"FDA approval package document: Pharmacology Review 021068, page:9 PDF 1522k",https://www.pharmapendium.com/browse/fda/Calcitriol/aa065acddbfdd79b59b251145b954611?reference=9,1998.0
48,73,353,Candesartan Cilexetil,CCOC1=NC2=CC=CC(C(=O)OC(C)OC(=O)OC3CCCCC3)=C2N1CC1=CC=C(C2=CC=CC=C2C2=NNN=N2)C=C1,Hepatomegaly,Rat,-1.0,Repeated,Oral,"FDA approval package document: Pharmacology Review 020838/S-000 Part 01, page:34 PDF 1562k",https://www.pharmapendium.com/browse/fda/Candesartan Cilexetil/da41fac278b6827ce487dbe45f52e6ea?reference=34,1998.0
49,74,354,Cannabidiol,C=C(C)C1CCC(C)=CC1C1=C(O)C=C(CCCCC)C=C1O,Hepatomegaly,Mouse,-2.2247919564926817,Repeated,Oral,"FDA approval package document: Pharmacology Review 210365/S-000, page:29 PDF 12775k",https://www.pharmapendium.com/browse/fda/Cannabidiol/2ca6aedc4b850302e03713d2ab8b19aa?reference=29,2018.0
50,76,371,Carbamazepine,NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C21,Hepatomegaly,Rat,-1.5740312677277188,Repeated,Oral,"FDA approval package document: Approval Package 018927/S-061, S-011, S-003, S-001, S-002, S-010, S-004, S-018, S-059, S-019 Part 01, page:33 PDF 4867k",https://www.pharmapendium.com/browse/fda/Carbamazepine/c72a28ad5effebdc76cd6f2d9ad3ec86?reference=33,1987.0
51,77,376,Carglumic Acid,NC(=O)NC(CCC(=O)O)C(=O)O,Hepatomegaly,Rat,-2.8239087409443187,Repeated,Oral,"FDA approval package document: Pharmacology Review 022562/S-000 Part 04, page:15 PDF 4470k",https://www.pharmapendium.com/browse/fda/Carglumic Acid/5715c822f5e5583890fe0d541762a880?reference=15,2010.0
52,79,393,Carisoprodol,CCCC(C)(COC(N)=O)COC(=O)NC(C)C,Hepatomegaly,Rat,-2.903089986991944,Repeated,Oral,"FDA approval package document: Approval Package 011792/S-041 Part 12, page:14 PDF 402k",https://www.pharmapendium.com/browse/fda/Carisoprodol/1a1908c9868c3814c5cf3286b691e831?reference=14,2007.0
53,80,398,Cefaloridine,O=C(CC1=CC=CS1)NC1C(=O)N2C(C(=O)[O-])=C(C[N+]3=CC=CC=C3)CSC12,Hepatomegaly,Rat,-1.484299839346786,Repeated,Subcutaneous,"Reference from PharmaPendium Published Toxicity: Toxicology and Applied Pharmacology 8,407,1966   ---   DOI:10.1016/0041-008X(66)90051-2   ISSN:0041-008X   JOURNAL:Toxicology and Applied Pharmacology   PAGES:407   VOLUME:8",http://dx.doi.org/10.1016/0041-008X(66)90051-2,1966.0
54,81,400,Cefditoren Pivoxil,CON=C(C(=O)NC1C(=O)N2C(C(=O)OCOC(=O)C(C)(C)C)=C(/C=C\C3=C(C)N=CS3)CSC12)C1=CSC(N)=N1,Hepatomegaly,Rat,-2.773603622632923,Repeated,Oral,"FDA approval package document: Pharmacology Review 021222/S-000, page:13 PDF 1253k",https://www.pharmapendium.com/browse/fda/Cefditoren Pivoxil/0901a16bcd5765996b9634b7443f3eae?reference=13,1999.0
55,82,404,Cefepime Hydrochloride,CON=C(C(=O)NC1C(=O)N2C(C(=O)O)=C(C[N+]3(C)CCCC3)CSC12)C1=CSC(N)=N1,Hepatomegaly,Rat,-3.0,Repeated,Intravenous,"FDA approval package document: Pharmacology Review 050817/S-000, page:14 PDF 1555k",https://www.pharmapendium.com/browse/fda/Cefepime Hydrochloride/0c30dfb84d60e51f9eba207fad913afa?reference=14,2007.0
56,83,405,Cefonicid Sodium,O=C(NC1C(=O)N2C(C(=O)O)C(=CSC3=NN=NN3CS(=O)(=O)O)CSC12)C(O)C1=CC=CC=C1,Hepatomegaly,Rat,-2.0,Repeated,Intraperitoneal,"FDA approval package document: Approval Package 050579 Part 03, page:37 PDF 5140k",https://www.pharmapendium.com/browse/fda/Cefonicid Sodium/4d65530ff33b4bbe08dbebadee5eaee0?reference=37,1984.0
57,84,407,Ceftazidime,CC(C)(ON=C(C(=O)NC1C(=O)N2C(C(=O)[O-])=C(C[N+]3=CC=CC=C3)CSC12)C1=CSC(N)=N1)C(=O)O,Hepatomegaly,Rat,-2.8750612633917,Repeated,Subcutaneous,"FDA approval package document: Approval Package 050578 Part 01, page:14 PDF 4762k",https://www.pharmapendium.com/browse/fda/Ceftazidime/1cd0911cf52fca25f2dc0e6329639eec?reference=14,1985.0
58,91,429,Cevimeline Hydrochloride,CC1OC2(CS1)CN1CCC2CC1,Hepatomegaly,Mouse,-1.6056641155967877,Repeated,Oral,"FDA approval package document: Pharmacology Review 020989/S-000, page:30 PDF 1384k",https://www.pharmapendium.com/browse/fda/Cevimeline Hydrochloride/65d27f8b802cefe5af3e7c4b49be1859?reference=30,1999.0
59,96,437,Ciclesonide,CC(C)C(=O)OCC(=O)C12OC(C3CCCCC3)OC1CC1C3CC=C4CC(=O)C=CC4(C)C3C(O)CC12C,Hepatomegaly,Rat,-8.92569876119301,Repeated,Inhalation,"FDA approval package document: Pharmacology Review 021658/S-000 Part 01, page:89 PDF 7036k",https://www.pharmapendium.com/browse/fda/Ciclesonide/0650561f95807aad73b20524047485ae?reference=89,2007.0
60,97,441,Ciclopirox,CC1=CC(=O)N(O)C(C2CCCCC2)=C1,Hepatomegaly,Rat,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Approval Package 018748 Part 02, page:48 PDF 5723k",https://www.pharmapendium.com/browse/fda/Ciclopirox/16ef7e32e16afc74aacf281177b7d9ef?reference=48,1982.0
61,98,442,Cidofovir,NC1=NC(=O)N(CC(CO)OC[PH](=O)(=O)O)C=C1,Hepatomegaly,Rat,-0.6989700043360189,Repeated,Intravenous,"FDA approval package document: Pharmacology Review 020638 Part 01, page:25 PDF 11015k",https://www.pharmapendium.com/browse/fda/Cidofovir/81389b7c8bc0142f8bc1942851b394e8?reference=25,1995.0
62,99,443,Cilostazol,O=C1CCC2=C(C=CC(OCCCCC3=NN=NN3C3CCCCC3)=C2)N1,Hepatomegaly,Rat,-1.4771212547196624,Repeated,Oral,"FDA approval package document: Pharmacology Review 020863/S-000 Part 02, page:8 PDF 2476k",https://www.pharmapendium.com/browse/fda/Cilostazol/48d400b3c32a0c02ff1de731c88448b2?reference=8,1998.0
63,110,469,Cobicistat,CC(C)C1=NC(CN(C)C(=O)NC(CCN2CCOCC2)C(=O)NC(CCC(CC2=CC=CC=C2)NC(=O)OCC2=CN=CS2)CC2=CC=CC=C2)=CS1,Hepatomegaly,Rat,-1.7958800173440752,Repeated,Oral,"FDA approval package document: Pharmacology Review 203094/S-000, page:34 PDF 4686k",https://www.pharmapendium.com/browse/fda/Cobicistat/fbd81667efa64e5238763760c47bacb4?reference=34,2012.0
64,112,474,Conivaptan Hydrochloride,CC1=NC2=C(N1)C1=CC=CC=C1N(C(=O)C1=CC=C(NC(=O)C3=CC=CC=C3C3=CC=CC=C3)C=C1)CC2,Hepatomegaly,Rat,-1.8129133566428557,Repeated,Intravenous,"FDA approval package document: Pharmacology Review 021697/S-000 Part 01, page:67 PDF 5313k",https://www.pharmapendium.com/browse/fda/Conivaptan Hydrochloride/860e08effb2fca2bf492f3fb05d05a2d?reference=67,2005.0
65,113,476,Copanlisib Dihydrochloride,COC1=C(OCCCN2CCOCC2)C=CC2=C3NCCN3C(=NC(=O)C3=CN=C(N)N=C3)N=C12,Hepatomegaly,Rat,-1.1903316981702914,Repeated,Intravenous,"FDA approval package document: Approval Package 209936/S-000 Part 02, page:11 PDF 11850k",https://www.pharmapendium.com/browse/fda/Copanlisib Dihydrochloride/3a7a918dba0779ad831f58c4b35fbbbb?reference=11,2017.0
66,114,478,Cromolyn Sodium,O=C(O)C1=CC(=O)C2=C(OCC(O)COC3=C4C(=O)C=C(C(=O)O)OC4=CC=C3)C=CC=C2O1,Hepatomegaly,Rat,-2.0,Repeated,Oral,"FDA approval package document: Approval Package 019188 Part 05, page:23 PDF 4102k",https://www.pharmapendium.com/browse/fda/Cromolyn Sodium/31283d355dc86c450a0ec448d4ca088d?reference=23,1989.0
67,115,479,Cyclosporine,C/C=C/CC(C)C(O)C1C(=O)NC(CC)C(=O)N(C)CC(=O)N(C)C(CC(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(CC(C)C)C(=O)NC(C)C(=O)NC(C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(C(C)C)C(=O)N1C,Hepatomegaly,Rat,-1.469822015978163,Repeated,Oral,"FDA approval package document: Approval Package 050573 Part 05, page:24 PDF 4615k",https://www.pharmapendium.com/browse/fda/Cyclosporine/558cdf3c238a582a6fe3255577f2d5c4?reference=24,1987.0
68,116,481,Daclatasvir Dihydrochloride,COC(=O)NC(C(=O)N1CCCC1C1=NC(C2=CC=C(C3=CC=C(C4=CNC(C5CCCN5C(=O)C(NC(=O)OC)C(C)C)=N4)C=C3)C=C2)=CN1)C(C)C,Hepatomegaly,Mouse,-2.5118833609788744,Repeated,Oral,"FDA approval package document: Pharmacology Review 206843/S-000, page:39 PDF 12236k",https://www.pharmapendium.com/browse/fda/Daclatasvir Dihydrochloride/98806d898b2994892ff5c8abf1d109db?reference=39,2014.0
69,117,485,Dalfampridine,NC1=CC=NC=C1,Hepatomegaly,Rat,-1.1383026981662814,Repeated,Oral,"FDA approval package document: Pharmacology Review 022250/S-000 Part 02, page:72 PDF 4011k",https://www.pharmapendium.com/browse/fda/Dalfampridine/dfa11509e5c15b05430d714406bd95e0?reference=72,2009.0
70,119,491,Dapsone,NC1=CC=C(S(=O)(=O)C2=CC=C(N)C=C2)C=C1,Hepatomegaly,Rat,-1.4771212547196624,Repeated,Oral,"FDA approval package document: Pharmacology Review 021794/S-000, page:21 PDF 4820k",https://www.pharmapendium.com/browse/fda/Dapsone/84a5aefeb182b4f043f7fa1cddd041d4?reference=21,2005.0
71,120,492,Darifenacin Hydrobromide,NC(=O)C(C1=CC=CC=C1)(C1=CC=CC=C1)C1CCN(CCC2=CC3=C(C=C2)OCC3)C1,Hepatomegaly,Rat,-1.6020599913279625,Repeated,Oral,"FDA approval package document: Pharmacology Review 021513/S-000, page:23 PDF 6496k",https://www.pharmapendium.com/browse/fda/Darifenacin Hydrobromide/86dfbf308572dac9237b9ebf65d553ad?reference=23,2001.0
72,121,494,Darunavir Ethanolate,CC(C)CN(CC(O)C(CC1=CC=CC=C1)NC(=O)OC1COC2OCCC12)S(=O)(=O)C1=CC=C(N)C=C1,Hepatomegaly,Rat,-2.0,Repeated,Oral,"FDA approval package document: Pharmacology Review 021976/S-000, page:20 PDF 5798k",https://www.pharmapendium.com/browse/fda/Darunavir Ethanolate/70ef46cb4572329a480d6ccc4a1debe2?reference=20,2006.0
73,123,499,Deferasirox,O=C(O)C1=CC=C(N2N=C(C3=CC=CC=C3O)N=C2C2=CC=CC=C2O)C=C1,Hepatomegaly,Rat,-2.0,Repeated,Oral,"FDA approval package document: Pharmacology Review 021882/S-000 Part 05, page:23 PDF 5087k",https://www.pharmapendium.com/browse/fda/Deferasirox/d1a1c6ddaae645a8fb28a3efec0c680e?reference=23,2005.0
74,124,504,Delavirdine Mesylate,CC(C)NC1=CC=CN=C1N1CCN(C(=O)C2=CC3=C(C=CC(NS(C)(=O)=O)=C3)N2)CC1,Hepatomegaly,Rat,-2.1826591646762967,Repeated,Oral,"FDA approval package document: Pharmacology Review 020705, page:26 PDF 1831k",https://www.pharmapendium.com/browse/fda/Delavirdine Mesylate/8ca8034d7edd97ba660b0908ff2e5d0f?reference=26,1996.0
75,126,541,Desonide,CC1(C)OC2CC3C4CC=C5CC(=O)C=CC5(C)C4C(O)CC3(C)C2(C(=O)CO)O1,Hepatomegaly,Rabbit,-3.4261315621742963,Repeated,Skin,"FDA approval package document: Pharmacology Review 021844/S-000, page:12 PDF 1666k",https://www.pharmapendium.com/browse/fda/Desonide/99c362704f73af616afeb35160e46ef0?reference=12,2006.0
76,128,546,Dexmedetomidine Hydrochloride,CC1=C(C)C(C(C)C2=CNC=N2)=CC=C1,Hepatomegaly,Rat,-7.698970004336019,Repeated,Intravenous,"FDA approval package document: Pharmacology Review 021038/S-000 Part 01, page:6 PDF 1373k",https://www.pharmapendium.com/browse/fda/Dexmedetomidine Hydrochloride/87578370044aeafc09bf641488550bf7?reference=6,1999.0
77,131,553,Diethylstilbestrol,CC=C(C1=CC=C(O)C=C1)C(CC)C1=CC=C(O)C=C1,Hepatomegaly,Mouse,-0.7403626894942439,Repeated,Intraperitoneal,"Reference from PharmaPendium Published Toxicity: toxicology letters 135,145,2002   ---   DOI:10.1016/S0378-4274(02)00256-4   ISSN:0378-4274   JOURNAL:Toxicology Letters   PAGES:145   VOLUME:135",http://dx.doi.org/10.1016/S0378-4274(02)00256-4,2002.0
78,132,555,Diltiazem Hydrochloride,COC1=CC=C(C2SC3=CC=CC=C3N(CCN(C)C)C(=O)C2OC(C)=O)C=C1,Hepatomegaly,Rat,-2.249198357391113,Repeated,Oral,"FDA approval package document: Pharmacology Review 020506 Part 01, page:8 PDF 752k",https://www.pharmapendium.com/browse/fda/Diltiazem Hydrochloride/a27221f091b5a5ec130b63487623f577?reference=8,1995.0
79,133,559,Diltiazem Malate,COC1=CC=C(C2SC3=C(C=CC=C3)N(CCN(C)C)C(=O)C2OC(C)=O)C=C1,Hepatomegaly,Rat,-1.7781512503836436,Repeated,Oral,"FDA approval package document: Pharmacology Review 020506 Part 01, page:6 PDF 752k",https://www.pharmapendium.com/browse/fda/Diltiazem Malate/a27221f091b5a5ec130b63487623f577?reference=6,1995.0
80,134,560,Dimethyl Fumarate,COC(=O)/C=C/C(=O)OC,Hepatomegaly,Rat,-2.0,Repeated,Oral,"FDA approval package document: Pharmacology Review 204063/S-000 Part 02, page:26 PDF 4324k",https://www.pharmapendium.com/browse/fda/Dimethyl Fumarate/0a52f3eb3439f8e6a112e4b304956b65?reference=26,2013.0
81,135,565,Docosanol,CCCCCCCCCCCCCCCCCCCCCCO,Hepatomegaly,Rabbit,-2.096910013008056,Repeated,Skin,"FDA approval package document: Pharmacology Review 020941/S-000 Part 02, page:2 PDF 1333k",https://www.pharmapendium.com/browse/fda/Docosanol/feca96e6ef1f7a197e61b5f83c1cd63d?reference=2,1999.0
82,136,567,Dolasetron Mesylate,O=C(OC1CC2CC3CC(C1)N2CC3=O)C1=CNC2=C1C=CC=C2,Hepatomegaly,Mouse,-2.331843943078201,Repeated,Oral,"FDA approval package document: Pharmacology Review 020623 Part 02, page:1 PDF 1851k",https://www.pharmapendium.com/browse/fda/Dolasetron Mesylate/872cda19b0673092705c2661812f9003?reference=1,1996.0
83,137,584,Doxercalciferol,C=C1/C(=C\C=C2/CCCC3(C)C2CCC3C(C)/C=C/C(C)C(C)C)CC(O)CC1O,Hepatomegaly,Rat,-6.397940442966302,Repeated,Intravenous,"FDA approval package document: Pharmacology Review 020862/S-000 Part 03, page:23 PDF 859k",https://www.pharmapendium.com/browse/fda/Doxercalciferol/d5cc9ad4ae0ec4ba3a3f45e0d6b88e15?reference=23,1999.0
84,138,586,Doxorubicin Hydrochloride,COC1=CC=CC2=C(O)C3=C(O)C4=CC(O)(C(=O)CO)CC(OC5CC(N)C(O)C(C)O5)=C4C(O)=C3C(O)=C12,Hepatomegaly,Rat,-0.9777236052888476,Repeated,Intraperitoneal,Reference from PharmaPendium Published Toxicity: 632188282   ---   DOI:10.22092/ARI.2019.116862.1177   ISSN:0365-3439   JOURNAL:Archives of Razi Institute   PAGES:55   VOLUME:75,http://dx.doi.org/10.22092/ARI.2019.116862.1177,2020.0
85,139,588,Dronedarone Hydrochloride,CCCCC1=C(C(=O)C2=CC=C(OCCCN(CCCC)CCCC)C=C2)C2=CC(NS(C)(=O)=O)=CC=C2O1,Hepatomegaly,Rat,-2.204119982655925,Repeated,Oral,"FDA approval package document: Pharmacology Review 022425/S-000 Part 02, page:108 PDF 3438k",https://www.pharmapendium.com/browse/fda/Dronedarone Hydrochloride/d8a13a7020f06e9ec9a3a334c32eeb45?reference=108,2009.0
86,140,589,Duloxetine Hydrochloride,CNCCC(OC1=CC=CC2=CC=CC=C12)C1=CC=CS1,Hepatomegaly,Rat,-1.6857417386022635,Repeated,Oral,"FDA approval package document: Pharmacology Review 021427/S-000 Part 02, page:35 PDF 1717k",https://www.pharmapendium.com/browse/fda/Duloxetine Hydrochloride/781bf9fca3c96273746112aa4cecce47?reference=35,2003.0
87,143,600,Eletriptan Hydrobromide,CN1CCCC1CC1=CNC2=C1C=C(CCS(=O)(=O)C1=CC=CC=C1)C=C2,Hepatomegaly,Mouse,-2.3891660843645326,Repeated,Oral,"FDA approval package document: Pharmacology Review 021016/S-000 Part 01, page:44 PDF 1977k",https://www.pharmapendium.com/browse/fda/Eletriptan Hydrobromide/f735f6506578d3a0425a66934cbf0624?reference=44,2002.0
88,144,602,Eltrombopag Olamine,CC1=CC=C(N2NC(C)=C(N=NC3=C(O)C(C4=CC=CC(C(=O)O)=C4)=CC=C3)C2=O)C=C1C,Hepatomegaly,Rat,-1.7596678446896306,Repeated,Oral,"FDA approval package document: Pharmacology Review 022291/S-000 Part 03, page:18 PDF 6636k",https://www.pharmapendium.com/browse/fda/Eltrombopag Olamine/d45fb8d502eba909ef3ff46fc2afd8a8?reference=18,2008.0
89,145,607,Emedastine Difumarate,CCOCCN1C(N2CCCN(C)CC2)=NC2=C1C=CC=C2,Hepatomegaly,Rat,-2.119475840906798,Repeated,Oral,"FDA approval package document: Pharmacology Review 020706/S-000, page:55 PDF 2395k",https://www.pharmapendium.com/browse/fda/Emedastine Difumarate/af910740475c9f3b7c8036e937d038b1?reference=55,1997.0
90,148,617,Encainide,COC1=CC=C(C(=O)NC2=CC=CC=C2CCC2CCCCN2C)C=C1,Hepatomegaly,Rat,-1.4471580313422192,Repeated,Oral,"FDA approval package document: Approval Package 018981 Part 07, page:18 PDF 4987k",https://www.pharmapendium.com/browse/fda/Encainide/6bc54f3217e981523d8002156ab6f728?reference=18,1986.0
91,149,618,Entecavir,C=C1C(CO)C(O)CC1N1C=NC2=C1N=C(N)NC2=O,Hepatomegaly,Rat,-0.4074853265782679,Repeated,Oral,"FDA approval package document: Pharmacology Review 021797/S-000, page:158 PDF 4991k",https://www.pharmapendium.com/browse/fda/Entecavir/33465dde950fca76b460013aa96dcbe2?reference=158,2004.0
92,151,628,Epirubicin Hydrochloride,COC1=C2C(O)=C3C(O)=C4C(OC5CC(N)C(O)C(C)O5)=CC(O)(C(=O)CO)CC4=C(O)C3=C(O)C2=CC=C1,Hepatomegaly,Rat,0.0,Repeated,Intravenous,"FDA approval package document: Pharmacology Review 050778/S-000, page:29 PDF 1432k",https://www.pharmapendium.com/browse/fda/Epirubicin Hydrochloride/1235d14363a2d308e69e13f490f4dc9e?reference=29,1999.0
93,152,630,Eplerenone,COC(=O)C1=CC2CC(=O)CCC2(C)C23OC2CC2(C)C(CCC24CCC(=O)O4)C13,Hepatomegaly,Mouse,-2.57978359661681,Repeated,Oral,"FDA approval package document: Pharmacology Review 021437/S-000 Part 03, page:2 PDF 1543k",https://www.pharmapendium.com/browse/fda/Eplerenone/479c85ace8cb2115be42b34583fe04a6?reference=2,
94,153,635,Ergonovine Maleate,CC(CO)NC(=O)C1=CC2C3=CC=CC4=C3C(=CN4)CC2N(C)C1,Hepatomegaly,Rat,-0.6020599913279624,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Food and Chemical Toxicology 34,951,1996   ---   DOI:10.1016/S0278-6915(96)00060-9   ISSN:0278-6915   JOURNAL:Food and Chemical Toxicology   PAGES:951   VOLUME:34",http://dx.doi.org/10.1016/S0278-6915(96)00060-9,1996.0
95,155,637,Eslicarbazepine Acetate,CC(=O)OC1CC2=C(C=CC=C2)N(C(N)=O)C2=C1C=CC=C2,Hepatomegaly,Rat,-2.0805363001325907,Repeated,Oral,"FDA approval package document: Pharmacology Review 022416/S-000 Part 08, page:24 PDF 4679k",https://www.pharmapendium.com/browse/fda/Eslicarbazepine Acetate/08cc1855ae2460ac9b2a72af5461b896?reference=24,2009.0
96,156,654,Esomeprazole Magnesium,COC1=CC2=C(C=C1)NC([S+]([O-])CC1=C(C)C(OC)=C(C)C=N1)=N2,Hepatomegaly,Rat,-2.4471580313422194,Repeated,Oral,"FDA approval package document: Pharmacology Review 021153/S-000, page:23 PDF 1652k",https://www.pharmapendium.com/browse/fda/Esomeprazole Magnesium/985419be37e47b879d52f6cc06fe74e0?reference=23,2000.0
97,157,656,Esomeprazole Sodium,COC1=CC2=C(C=C1)NC([S+]([O-])CC1=NC=C(C)C(OC)=C1C)=N2,Hepatomegaly,Rat,-2.0791812460476247,Repeated,Intravenous,"FDA approval package document: Pharmacology Review 021689/S-000, page:30 PDF 7706k",https://www.pharmapendium.com/browse/fda/Esomeprazole Sodium/7810e15b399f55edb2f5aa587ceae5d0?reference=30,2004.0
98,159,663,Estradiol,CC12CCC3C4=C(C=C(O)C=C4)CCC3C1CCC2O,Hepatomegaly,Rat,-0.6532125137753437,Repeated,Oral,"FDA approval package document: Approval Package 201675/S-000 Part 02, page:57 PDF 14435k",https://www.pharmapendium.com/browse/fda/Estradiol/13c11f12b3248e4bf786d0c6db70732a?reference=57,2014.0
99,161,688,Ethinyl Estradiol,C#CC1(O)CCC2C3CCC4=C(C=CC(O)=C4)C3CCC21C,Hepatomegaly,Rat,-0.7781512503836436,Repeated,Subcutaneous,Reference from PharmaPendium Published Toxicity: ethinyl estradiol01224.full   ---   JOURNAL:Cancer Research   PAGES:1224   VOLUME:46,,1986.0
100,162,690,Etodolac,CCC1=CC=CC2=C1NC1=C2CCOC1(CC)CC(=O)O,Hepatomegaly,Rat,-1.1760912590556811,Repeated,Oral,"FDA approval package document: Approval Package 018922/S-007, S-008, S-013, S-014, S-015 Part 03, page:18 PDF 4842k",https://www.pharmapendium.com/browse/fda/Etodolac/b5d199e81bd6e805987591bcb27a0df4?reference=18,1991.0
101,163,691,Etoposide,COC1=C(O)C(OC)=CC(C2C3=CC4=C(C=C3C(OC3OC5COC(C)OC5C(O)C3O)C3COC(=O)C23)OCO4)=C1,Hepatomegaly,Rat,-0.9030899869919436,Repeated,Intravenous,"FDA approval package document: Approval Package 018768/S-001, S-017, S-025, S-026, S-030; 019557/S-006, S-009, S-010, S-015 Part 01, page:40 PDF 4695k",https://www.pharmapendium.com/browse/fda/Etoposide/b48d5040f522ad36061268a6445c529d?reference=40,1983.0
102,164,692,Etoposide Phosphate,COC1=C(O[PH](=O)(=O)O)C(OC)=CC(C2C3=CC4=C(C=C3C(OC3OC5COC(C)OC5C(O)C3O)C3COC(=O)C23)OCO4)=C1,Hepatomegaly,Mouse,-0.6989700043360189,Repeated,Intraperitoneal,"FDA approval package document: Pharmacology Review 020457, page:20 PDF 852k",https://www.pharmapendium.com/browse/fda/Etoposide Phosphate/77163edfab257828ec4d561e8a14857f?reference=20,1996.0
103,166,700,Everolimus,COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(OCCO)C(OC)C2)CC(=O)C(C)=CC(C)C(O)C(OC)C(=O)C(C)CC(C)/C=C/C=C/C=C/1C,Hepatomegaly,Rat,-1.1760912590556811,Repeated,Oral,"FDA approval package document: Pharmacology Review 022334/S-000, page:49 PDF 10405k",https://www.pharmapendium.com/browse/fda/Everolimus/e46643d0f24958522e729d0eb9b739f9?reference=49,2009.0
104,168,703,Famciclovir,CC(=O)OCC(CCN1C=NC2=C1N=C(N)N=C2)COC(C)=O,Hepatomegaly,Rat,-1.6020599913279625,Repeated,Oral,"FDA approval package document: Pharmacology Review 020363, page:5 PDF 922k",https://www.pharmapendium.com/browse/fda/Famciclovir/d8801c975b5dc0291806cc19b8901e08?reference=5,1996.0
105,169,704,Felbamate,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,Hepatomegaly,Rat,-2.4149733479708178,Repeated,Oral,"FDA approval package document: Pharmacology Review 020189 Part 04, page:19 PDF 898k",https://www.pharmapendium.com/browse/fda/Felbamate/529e4280efbc989870e43a12b5f92860?reference=19,1993.0
106,173,728,Fentanyl Hydrochloride,CCC(=O)N(C1=CC=CC=C1)C1CCN(CCC2=CC=CC=C2)CC1,Hepatomegaly,Rat,-0.6020599913279624,Repeated,Intravenous,"FDA approval package document: Pharmacology Review 021338/S-000 Part 01, page:63 PDF 5808k",https://www.pharmapendium.com/browse/fda/Fentanyl Hydrochloride/83f4bf287704ac87f1b0c784783dabdc?reference=63,2006.0
107,174,731,Fesoterodine Fumarate,CC(C)C(=O)OC1=CC=C(CO)C=C1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1,Hepatomegaly,Rat,-1.3979400086720375,Repeated,Oral,"EMA approval document: Scientific Discussion, page:10 PDF 570k",https://www.pharmapendium.com/browse/ema/Fesoterodine Fumarate/238fbea499fffe13d66505b309802cbe?reference=10,2007.0
108,175,732,Finasteride,CC(C)(C)NC(=O)C1CCC2C3CCC4NC(=O)C=CC4(C)C3CCC12C,Hepatomegaly,Rat,-1.2218487496163566,Repeated,Oral,"FDA approval package document: Approval Package 020180 Part 04, page:7 PDF 5649k",https://www.pharmapendium.com/browse/fda/Finasteride/ec9515d5a72115afa1e58e97f9346eaf?reference=7,1992.0
109,185,777,Fondaparinux Sodium,COC1OC(COS(=O)(=O)O)C(OC2OC(C(=O)O)C(OC3OC(COS(=O)(=O)O)C(OC4OC(C(=O)O)C(OC5OC(COS(=O)(=O)O)C(O)C(O)C5NS(=O)(=O)O)C(O)C4O)C(OS(=O)(=O)O)C3NS(=O)(=O)O)C(O)C2OS(=O)(=O)O)C(O)C1NS(=O)(=O)O,Hepatomegaly,Rat,-1.0,Repeated,Subcutaneous,"FDA approval package document: Pharmacology Review 021345/S-000 Part 02, page:25 PDF 1712k",https://www.pharmapendium.com/browse/fda/Fondaparinux Sodium/944979fb1554aed80fc853a4961e67c8?reference=25,2001.0
110,186,778,Formoterol Fumarate,COC1=CC=C(CC(C)NCC(O)C2=CC=C(O)C(NC=O)=C2)C=C1,Hepatomegaly,Rat,-2.081587315813503,Repeated,Oral,"FDA approval package document: Pharmacology Review 020831/S-000 Part 05, page:4 PDF 916k",https://www.pharmapendium.com/browse/fda/Formoterol Fumarate/b92d18637332793921e3e2a3ed371d05?reference=4,2000.0
111,187,795,Fosamprenavir Calcium,CC(C)CN(CC(O[PH](=O)(=O)O)C(CC1=CC=CC=C1)NC(=O)OC1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1,Hepatomegaly,Rat,-2.9080311028032235,Repeated,Oral,"FDA approval package document: Pharmacology Review 021548/S-000 Part 03, page:3 PDF 1596k",https://www.pharmapendium.com/browse/fda/Fosamprenavir Calcium/742de3ff271fc37c80260f31a62784fa?reference=3,2003.0
112,189,817,Fosfomycin Tromethamine,NC(CO)(CO)CO,Hepatomegaly,Rat,-3.39503501802863,Repeated,Oral,"FDA approval package document: Pharmacology Review 050717, page:7 PDF 1714k",https://www.pharmapendium.com/browse/fda/Fosfomycin Tromethamine/cd20241537c3ba601ca3447f0d523c9e?reference=7,1995.0
113,190,820,Fosinopril Sodium,CCC(=O)OC(OP(=O)(CCCCC1=CC=CC=C1)CC(=O)N1CC(C2CCCCC2)CC1C(=O)O)C(C)C,Hepatomegaly,Rat,-2.0,Repeated,Oral,"FDA approval package document: Pharmacology Review 019915 Part 04, page:6 PDF 985k",https://www.pharmapendium.com/browse/fda/Fosinopril Sodium/228f17b43cfc9fd36d2a83d56cc4036c?reference=6,1991.0
114,191,822,Fosphenytoin Sodium,O=C1NC(C2=CC=CC=C2)(C2=CC=CC=C2)C(=O)N1CO[PH](=O)(=O)O,Hepatomegaly,Rat,-1.6812412373755872,Repeated,Intramuscular,"FDA approval package document: Pharmacology Review 020450, page:53 PDF 2321k",https://www.pharmapendium.com/browse/fda/Fosphenytoin Sodium/b9572b14dae0809e2e4995fa0c8b37b2?reference=53,1995.0
115,193,830,Fostemsavir Tromethamine,COC1=C2C(C(=O)C(=O)N3CCN(C(=O)C4=CC=CC=C4)CC3)=CN(CO[PH](=O)(=O)O)C2=C(N2C=NC(C)=N2)N=C1,Hepatomegaly,Rat,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 212950/S-000 Part 13, page:6 PDF 3446k",https://www.pharmapendium.com/browse/fda/Fostemsavir Tromethamine/1227423496b972175f249eb77598e38c?reference=6,2019.0
116,194,832,Gabapentin,NCC1(CC(=O)O)CCCCC1,Hepatomegaly,Rat,-3.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 020235 Part 05, page:74 PDF 7126k",https://www.pharmapendium.com/browse/fda/Gabapentin/cc544275f43b7ddbd40fd331f4f68e5a?reference=74,1993.0
117,195,836,Galantamine Hydrobromide,COC1=CC=C2CN(C)CCC34C=CC(O)CC3OC1=C24,Hepatomegaly,Mouse,-1.0,Repeated,Oral,"FDA approval package document: Pharmacology Review 021169/S-000 Part 01, page:65 PDF 1642k",https://www.pharmapendium.com/browse/fda/Galantamine Hydrobromide/d69f07b8f67d9fc1fa283fdde2b936c5?reference=65,2000.0
118,199,844,Glimepiride,CCC1=C(O)N(C(=O)NCCC2=CC=C(S(=O)(=O)NC(=O)NC3CCC(C)CC3)C=C2)C=C1C,Hepatomegaly,Mouse,-2.3201462861110542,Repeated,Oral,"FDA approval package document: Pharmacology Review 020496, page:17 PDF 972k",https://www.pharmapendium.com/browse/fda/Glimepiride/14b0f5e77295b2407f28f021ec55b510?reference=17,1995.0
119,200,845,Glucagon,CSCCC(NC(=O)C(CC(C)C)NC(=O)C(CC1=CC=C(O)C=C1)NC(=O)C(CCC(N)=O)NC(=O)C(NC(=O)C(CC1=CC=CC=C1)NC(=O)C(CC(=O)O)NC(=O)C(CCC(N)=O)NC(=O)C(C)NC(=O)C(CCCN=C(N)N)NC(=O)C(CCCN=C(N)N)NC(=O)C(CO)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC1=CC=C(O)C=C1)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC1=CC=C(O)C=C1)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC1=CC=CC=C1)NC(=O)C(NC(=O)CNC(=O)C(CCC(N)=O)NC(=O)C(CO)NC(=O)C(N)CC1=CNC=N1)C(C)O)C(C)O)C(C)C)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)O)C(C)O,Hepatomegaly,Rat,-1.070037866607755,Repeated,Subcutaneous,"EMA approval document: Public Assessment Report EMA/6676/2021; EMEA/H/C/005391/0000, page:23 PDF 3531k",https://www.pharmapendium.com/browse/ema/Glucagon/e6e7e02ddb716e8f83851b484a3d0dd4?reference=23,2020.0
120,202,856,Glycerol Phenylbutyrate,O=C(CCCC1=CC=CC=C1)OCC(COC(=O)CCCC1=CC=CC=C1)OC(=O)CCCC1=CC=CC=C1,Hepatomegaly,Rat,-4.665893545534432,Repeated,Oral,"FDA approval package document: Pharmacology Review 203284/S-000 Part 09, page:16 PDF 3369k",https://www.pharmapendium.com/browse/fda/Glycerol Phenylbutyrate/49fa5483c7e79c349351b4d2b7e6b28d?reference=16,2012.0
121,203,859,Granisetron,CN1C2CCCC1CC(NC(=O)C1=NN(C)C3=C1C=CC=C3)C2,Hepatomegaly,Rat,-1.9420080530223127,Repeated,Oral,"FDA approval package document: Pharmacology Review 022198/S-000, page:50 PDF 4033k",https://www.pharmapendium.com/browse/fda/Granisetron/aeb89a6899d842b3f0fa9b7a0295df59?reference=50,2007.0
122,206,863,Histamine Dihydrochloride,NCCC1=CNC=N1,Hepatomegaly,Rat,-2.3010299956639813,Repeated,Subcutaneous,"EMA approval document: Assessment Report EMEA/CHMP/520543/2008, page:16 PDF 1128k",https://www.pharmapendium.com/browse/ema/Histamine Dihydrochloride/15fcfc129bfa497333e828f3b6c11bf1?reference=16,2008.0
123,207,864,Hydrocortisone,CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)CO,Hepatomegaly,Rabbit,-1.1760912590556811,Repeated,Intramuscular,"EMA approval document: Assessment Report EMA/CHMP/424438/2011; EMEA/H/C/2185, page:17 PDF 888k",https://www.pharmapendium.com/browse/ema/Hydrocortisone/4e60a37ae57756d34dd06c403ec4c55e?reference=17,2011.0
124,208,865,Hydrocortisone Butyrate,CCCC(=O)OC1(C(=O)CO)CCC2C3CC=C4CC(=O)CCC4(C)C3C(O)CC21C,Hepatomegaly,Rat,-0.3010299956639812,Repeated,Subcutaneous,"FDA approval package document: Pharmacology Review 020769, page:7 PDF 1103k",https://www.pharmapendium.com/browse/fda/Hydrocortisone Butyrate/71c2f56e2324b860f122ffa106d0c45d?reference=7,1981.0
125,209,866,Hydroquinone,OC1=CC=C(O)C=C1,Hepatomegaly,Mouse,-2.6020599913279625,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Food and Chemical Toxicology 30,737,1992   ---   DOI:10.1016/0278-6915(92)90075-V   ISSN:0278-6915   JOURNAL:Food and Chemical Toxicology   PAGES:737   VOLUME:30",http://dx.doi.org/10.1016/0278-6915(92)90075-V,1992.0
126,210,867,Ibandronate Sodium,CCCCCN(C)CCC(O)([PH](=O)(=O)O)[PH](=O)(=O)O,Hepatomegaly,Rat,-0.0,Repeated,Oral,"FDA approval package document: Pharmacology Review 021858/S-000, page:29 PDF 5448k",https://www.pharmapendium.com/browse/fda/Ibandronate Sodium/8f50c8047da054cc06a0b520b31e3d31?reference=29,2005.0
127,211,868,Ibuprofen,CC(C)CC1=CC=C(C(C)C(=O)O)C=C1,Hepatomegaly,Mouse,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Approval Package 017463/S-034, S-063, S-049, S-052, S-097, S-098, S-095; 019012/S-013 Part 01, page:9 PDF 4908k",https://www.pharmapendium.com/browse/fda/Ibuprofen/d16be14be7684a5a7e82ebbf532ebe1d?reference=9,1982.0
128,212,870,Ibutilide Fumarate,CCCCCCCN(CC)CCCC(O)C1=CC=C(NS(C)(=O)=O)C=C1,Hepatomegaly,Rat,-1.6989700043360187,Repeated,Intravenous,"FDA approval package document: Pharmacology Review 020491 Part 02, page:5 PDF 1558k",https://www.pharmapendium.com/browse/fda/Ibutilide Fumarate/9b7aefc0bf53823ab3917c755d4eebff?reference=5,1995.0
129,213,872,Icatibant Acetate,N=C(N)NCCCC(N)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)N1CC(O)CC1C(=O)NCC(=O)NC(CC1=CC=CS1)C(=O)NC(CO)C(=O)N1CC2=CC=CC=C2CC1C(=O)N1C(C(=O)NC(CCCN=C(N)N)C(=O)O)CC2CCCCC21,Hepatomegaly,Mouse,-1.3979400086720375,Repeated,Subcutaneous,"FDA approval package document: Pharmacology Review 022150/S-000 Part 05, page:15 PDF 897k",https://www.pharmapendium.com/browse/fda/Icatibant Acetate/df2dc8c42afba05284d96287d75f8ce5?reference=15,2007.0
130,214,873,Icosapent Ethyl,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OCC,Hepatomegaly,Rat,-3.6020599913279625,Repeated,Oral,"FDA approval package document: Pharmacology Review 202057/S-000 Part 02, page:31 PDF 4715k",https://www.pharmapendium.com/browse/fda/Icosapent Ethyl/871607c88ef2c24ae8ca008e6956ebad?reference=31,2011.0
131,216,877,Iloprost,CC#CCC(C)C(O)/C=C/C1C(O)CC2C/C(=C\CCCC(=O)O)CC21,Hepatomegaly,Rat,-2.096910013008056,Repeated,Oral,"FDA approval package document: Pharmacology Review 021779/S-000, page:89 PDF 5048k",https://www.pharmapendium.com/browse/fda/Iloprost/c9e7deb0883533598a7f647960c0e873?reference=89,2004.0
132,217,878,Indinavir Sulfate,CC(C)(C)NC(=O)C1CN(CC2=CC=CN=C2)CCN1CC(O)CC(CC1=CC=CC=C1)C(=O)NC1C2=CC=CC=C2CC1O,Hepatomegaly,Rat,-2.584331224367531,Repeated,Oral,"FDA approval package document: Pharmacology Review 020685, page:25 PDF 2098k",https://www.pharmapendium.com/browse/fda/Indinavir Sulfate/d214ba9ff666ee648ab3c78ad1eff978?reference=25,1996.0
133,218,884,Ingenol Mebutate,CC=C(C)C(=O)OC1C(C)=CC23C(=O)C(=CC(CO)C(O)C12O)C1C(CC3C)C1(C)C,Hepatomegaly,Rat,-6.698970004336019,Repeated,Intravenous,"FDA approval package document: Pharmacology Review 202833/S-000 Part 06, page:14 PDF 2905k",https://www.pharmapendium.com/browse/fda/Ingenol Mebutate/58c13f86fc55af39ae2f23b84fd3052f?reference=14,2011.0
134,219,885,Iobenguane Sulfate I 131,N=C(N)NCC1=CC([131I])=CC=C1,Hepatomegaly,Rat,-1.3010299956639813,Repeated,Intravenous,"FDA approval package document: Approval Package 020084 Part 02, page:20 PDF 7833k",https://www.pharmapendium.com/browse/fda/Iobenguane Sulfate I 131/26e5d1f5db398eb4d0478bc8501e4443?reference=20,1994.0
135,220,886,Irbesartan,CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C2=CC=CC=C2C2=NNN=N2)C=C1,Hepatomegaly,Mouse,-2.745966567012242,Repeated,Oral,"FDA approval package document: Pharmacology Review 020757/S-000 Part 02, page:73 PDF 3036k",https://www.pharmapendium.com/browse/fda/Irbesartan/4db01d512b5ac047c9bdf97b6883d20c?reference=73,1997.0
136,222,910,Istradefylline,CCN1C(=O)C2=C(N=C(/C=C/C3=CC=C(OC)C(OC)=C3)N2C)N(CC)C1=O,Hepatomegaly,Mouse,-2.3138672203691533,Repeated,Oral,"FDA approval package document: Pharmacology Review 022075/S-000 Part 05, page:16 PDF 1544k",https://www.pharmapendium.com/browse/fda/Istradefylline/d8b03659fddbd0b10be83393532e44a0?reference=16,2008.0
137,224,920,Ivabradine Hydrochloride,COC1=C(OC)C=C2CC(=O)N(CCCN(C)CC3CC4=C3C=C(OC)C(OC)=C4)CCC2=C1,Hepatomegaly,Rat,-1.1949766032160551,Repeated,Oral,"FDA approval package document: Pharmacology Review 206143/S-000, page:112 PDF 43271k",https://www.pharmapendium.com/browse/fda/Ivabradine Hydrochloride/edc1083dfcdf1c91d99c140c08bdd9c9?reference=112,2014.0
138,225,923,Ivacaftor,CC(C)(C)C1=C(O)C=C(NC(=O)C2=CNC3=CC=CC=C3C2=O)C(C(C)(C)C)=C1,Hepatomegaly,Rat,-2.375663613960885,Repeated,Oral,"FDA approval package document: Pharmacology Review 203188/S-000 Part 07, page:4 PDF 3049k",https://www.pharmapendium.com/browse/fda/Ivacaftor/12c4846d1e04ff23e1995691bb7f78f9?reference=4,2012.0
139,228,932,Josamycin,COC1C(OC(C)=O)CC(=O)OC(C)C/C=C\C=C\C(O)C(C)CC(CC=O)C1OC1OC(C)C(OC2CC(C)(O)C(OC(=O)CC(C)C)C(C)O2)C(N(C)C)C1O,Hepatomegaly,Rat,-1.3979400086720375,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Food and Chemical Toxicology 40,1017,2001   ---   DOI:10.1016/S0278-6915(02)00068-6   ISSN:0278-6915   JOURNAL:Food and Chemical Toxicology   PAGES:1017   VOLUME:40",http://dx.doi.org/10.1016/S0278-6915(02)00068-6,2001.0
140,229,933,Ketorolac Tromethamine,O=C(C1=CC=CC=C1)C1=CC=C2C(C(=O)O)CCN12,Hepatomegaly,Mouse,-1.4771212547196624,Repeated,Oral,"FDA approval package document: Approval Package 019645/S-001 Part 01, page:18 PDF 4498k",https://www.pharmapendium.com/browse/fda/Ketorolac Tromethamine/75a3fc8abc5250efabeb6d70d8688772?reference=18,1987.0
141,230,934,Ketotifen Fumarate,CN1CCC(=C2C3=CC=CC=C3CC(=O)C3=C2C=CS3)CC1,Hepatomegaly,Rat,-1.9614210940664485,Repeated,Oral,"FDA approval package document: Pharmacology Review 021066/S-000 Part 01, page:46 PDF 1907k",https://www.pharmapendium.com/browse/fda/Ketotifen Fumarate/19101dc7f3d2cfe9ddb912c2f47b808c?reference=46,1999.0
142,231,938,Lacosamide,COCC(NC(C)=O)C(=O)NCC1=CC=CC=C1,Hepatomegaly,Rat,-2.3010299956639813,Repeated,Oral,"EMA approval document: Assessment Report EMEA/460925/2008, page:20 PDF 1529k",https://www.pharmapendium.com/browse/ema/Lacosamide/0c41fd7a2d59a3b4ce8cf9f56dfda3a2?reference=20,2008.0
143,232,941,Lactitol,OCC(O)C(O)C(OC1OC(CO)C(O)C(O)C1O)C(O)CO,Hepatomegaly,Rat,-3.903089986991944,Repeated,Oral,"FDA approval package document: Approval Package 211281/S-000 Part 01, page:38 PDF 1307k",https://www.pharmapendium.com/browse/fda/Lactitol/29fc08cc768baf5b044489d48fa6a036?reference=38,2020.0
144,240,987,Letrozole,N#CC1=CC=C(C(C2=CC=C(C#N)C=C2)N2C=NC=N2)C=C1,Hepatomegaly,Rat,-0.981738683025684,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020726 Part 01, page:21 PDF 3469k",https://www.pharmapendium.com/browse/fda/Letrozole/72bacd76e87e03b74f76cae96cafa6eb?reference=21,1996.0
145,241,1006,Leuprolide Acetate,CCNC(=O)C1CCCN1C(=O)C(CCCNC(=N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC1=CC=C(O)C=C1)NC(=O)C(CO)NC(=O)C(CC1=CNC2=C1C=CC=C2)NC(=O)C(CC1=CNC=N1)NC(O)C1=CC=C(O)N1,Hepatomegaly,Rat,-1.230448921378274,Repeated,Intramuscular,"FDA approval package document: Approval Package 205054/S-000 Part 04, page:62 PDF 4902k",https://www.pharmapendium.com/browse/fda/Leuprolide Acetate/23544003525d68851f4d9c8202ebaede?reference=62,2015.0
146,242,1007,Levetiracetam,CCC(C(N)=O)N1CCCC1=O,Hepatomegaly,Rat,-3.017902450018896,Repeated,Oral,"FDA approval package document: Pharmacology Review 021035, page:24 PDF 1699k",https://www.pharmapendium.com/browse/fda/Levetiracetam/fe534fda88fabd4471d10e41769e737b?reference=24,1999.0
147,244,1021,Levomilnacipran Hydrochloride,CCN(CC)C(=O)C1(C2=CC=CC=C2)CC1CN,Hepatomegaly,Rat,-2.0791812460476247,Repeated,Oral,"FDA approval package document: Pharmacology Review 204168/S-000 Part 02, page:148 PDF 16517k",https://www.pharmapendium.com/browse/fda/Levomilnacipran Hydrochloride/af3376891ab8ae9c5f743692525cd591?reference=148,2012.0
148,254,1060,Mebendazole,COC(=O)NC1=NC2=C(C=CC(C(=O)C3=CC=CC=C3)=C2)N1,Hepatomegaly,Rat,-1.8512583487190752,Repeated,Oral,"FDA approval package document: Pharmacology Review 208398/S-000 Part 01, page:24 PDF 6193k",https://www.pharmapendium.com/browse/fda/Mebendazole/cb026f8ef7ebfa8de1bfa1885a666900?reference=24,2016.0
149,256,1064,Megestrol Acetate,CC(=O)OC1(C(C)=O)CCC2C3=CC(C)=C4CC(=O)CCC4(C)C3CCC21C,Hepatomegaly,Rat,-0.4771212547196624,Repeated,Oral,"FDA approval package document: Pharmacology Review 021778/S-000, page:26 PDF 3229k",https://www.pharmapendium.com/browse/fda/Megestrol Acetate/150bb511b7c6f352ddf19a1d9072f725?reference=26,2005.0
150,257,1065,Melatonin,COC1=CC2=C(C=C1)NC=C2CCNC(C)=O,Hepatomegaly,Rat,-2.165095874754218,Repeated,Oral,"EMA approval document: Assessment Report EMEA/H/C/695, page:13 PDF 343k",https://www.pharmapendium.com/browse/ema/Melatonin/585ed2d7b74236b30fda4c265b4c9b2c?reference=13,2007.0
151,258,1069,Memantine Hydrochloride,CC12CC3CC(C)(C1)CC(N)(C3)C2,Hepatomegaly,Rat,-1.6532125137753435,Repeated,Oral,"FDA approval package document: Pharmacology Review 021487/S-000 Part 05, page:2 PDF 1822k",https://www.pharmapendium.com/browse/fda/Memantine Hydrochloride/46d984a4197aa52894750f8adda4767d?reference=2,2003.0
152,259,1076,Mephenoxalone,COC1=CC=CC=C1OCC1CNC(=O)O1,Hepatomegaly,Rat,-1.3222192947339193,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: toxicology and applied pharmacology 6,642,1964   ---   DOI:10.1016/0041-008X(64)90114-0   ISSN:0041-008X   JOURNAL:Toxicology and Applied Pharmacology   PAGES:642   VOLUME:6",http://dx.doi.org/10.1016/0041-008X(64)90114-0,1964.0
153,260,1077,Mesalamine,NC1=CC(C(=O)O)=C(O)C=C1,Hepatomegaly,Mouse,-3.6020599913279625,Repeated,Oral,"FDA approval package document: Pharmacology Review 019651/S-005 Part 01, page:7 PDF 905k",https://www.pharmapendium.com/browse/fda/Mesalamine/f217d6c99465f9c255603ef473530cae?reference=7,1997.0
154,261,1078,Methoxsalen,COC1=C2OC(=O)C=CC2=CC2=C1OC=C2,Hepatomegaly,Rat,-1.9938769149412112,Repeated,Oral,"FDA approval package document: Pharmacology Review 020969, page:27 PDF 1403k",https://www.pharmapendium.com/browse/fda/Methoxsalen/e41b4bd3ba06420fe6033629330f4767?reference=27,1999.0
155,262,1083,Methyl Aminolevulinate Hydrochloride,COC(=O)CCC(=O)CN,Hepatomegaly,Rat,-2.628388930050312,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 021415/S-000, page:88 PDF 8861k",https://www.pharmapendium.com/browse/fda/Methyl Aminolevulinate Hydrochloride/205400cdd15a85be2b5b4e35f2861c3a?reference=88,2004.0
156,263,1085,Methylene Blue,CN(C)C1=CC2=C(C=C1)N=C1C=CC(=[N+](C)C)C=C1S2,Hepatomegaly,Rat,-2.210853365314893,Repeated,Oral,"FDA approval package document: Pharmacology Review 204630/S-000, page:68 PDF 11848k",https://www.pharmapendium.com/browse/fda/Methylene Blue/3cd56d6469a1096eecf27d16de67a916?reference=68,2013.0
157,264,1087,Methylprednisolone Sodium Succinate,CC1=C2CC(=O)C=CC2(C)C2C(O)CC3(C)C(CCC3(O)C(=O)COC(=O)CCC(=O)O)C2C1,Hepatomegaly,Rat,-0.8450980400142568,Repeated,Implant,"Reference from PharmaPendium Published Toxicity: Journal of Pharmacology and Experimental Therapeutics 300,245,2002   ---   DOI:10.1124/JPET.300.1.245   JOURNAL:Journal of Pharmacology and Experimental Therapeutics   PAGES:245   VOLUME:300",http://dx.doi.org/10.1124/JPET.300.1.245,2002.0
158,265,1088,Methyltestosterone,CC12CCC(=O)C=C1CCC1C2CCC2(C)C1CCC2(C)O,Hepatomegaly,Rat,-1.0,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Toxicology 186,227,2003   ---   DOI:10.1016/S0300-483X(02)00750-3   ISSN:0300-483X   JOURNAL:Toxicology   PAGES:227   VOLUME:186",http://dx.doi.org/10.1016/S0300-483X(02)00750-3,2003.0
159,267,1091,Mexiletine Hydrochloride,CC1=C(OCC(C)N)C(C)=CC=C1,Hepatomegaly,Rat,-2.397940008672037,Repeated,Oral,"EMA approval document: Public Assessment Report EMA/831802/2018; EMEA/H/C/004584/0000, page:24 PDF 3055k",https://www.pharmapendium.com/browse/ema/Mexiletine Hydrochloride/0339e2432f1279187517a7d5ce5d49a6?reference=24,2018.0
160,272,1106,Mifepristone,CC#CC1(O)CCC2C3=C(C4=C(CC3)CC(=O)CC4)C(C3=CC=C(N(C)C)C=C3)CC21C,Hepatomegaly,Mouse,-1.740362689494244,Repeated,Oral,"FDA approval package document: Pharmacology Review 202107/S-000 Part 04, page:41 PDF 7149k",https://www.pharmapendium.com/browse/fda/Mifepristone/3462b48517ccc84185c9dd06f991e8f1?reference=41,2012.0
161,273,1110,Miglitol,OCCN1CC(O)C(O)C(O)C1CO,Hepatomegaly,Rat,-3.0,Repeated,Oral,"FDA approval package document: Pharmacology Review 020682, page:5 PDF 1173k",https://www.pharmapendium.com/browse/fda/Miglitol/fb5f8f25f9a4e91a066eddf6fa97642c?reference=5,
162,274,1111,Miglustat,CCCCN1CC(O)C(O)C(O)C1CO,Hepatomegaly,Mouse,-3.03154310833328,Repeated,Oral,"FDA approval package document: Pharmacology Review 021348/S-000 Part 01, page:5 PDF 1250k",https://www.pharmapendium.com/browse/fda/Miglustat/c6a2b7752cd599c68628190dc5d18ae6?reference=5,2003.0
163,275,1141,Miltefosine,CCCCCCCCCCCCCCCCOP(=O)([O-])OCC[N+](C)(C)C,Hepatomegaly,Rat,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Pharmacology Review 204684/S-000 Part 02, page:3 PDF 335k",https://www.pharmapendium.com/browse/fda/Miltefosine/ce0de14473507b05f8d9047be3725f66?reference=3,2013.0
164,276,1143,Minocycline Hydrochloride,CN(C)C1=CC=C(O)C2=C1CC1CC3C(N(C)C)C(=O)C(C(N)=O)C(=O)C3(O)C(=O)C1C2=O,Hepatomegaly,Rat,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Pharmacology Review 050808/S-000, page:24 PDF 3377k",https://www.pharmapendium.com/browse/fda/Minocycline Hydrochloride/985df054ef4b7aae2e8e5a6db7c255a4?reference=24,2005.0
165,277,1144,Minoxidil,NC1=CC(N2CCCCC2)=NC(N)=[N+]1[O-],Hepatomegaly,Rat,-1.499687082618404,Repeated,Topical,"FDA approval package document: Pharmacology Review 021812/S-000, page:21 PDF 1628k",https://www.pharmapendium.com/browse/fda/Minoxidil/ec1a9dc09fffb0e1e912162324b2ec31?reference=21,2005.0
166,278,1150,Mirabegron,NC1=NC(CC(=O)NC2=CC=C(CCNCC(O)C3=CC=CC=C3)C=C2)=CS1,Hepatomegaly,Rat,-1.619788758288394,Repeated,Oral,"FDA approval package document: Pharmacology Review 202611/S-000 Part 05, page:10 PDF 13640k",https://www.pharmapendium.com/browse/fda/Mirabegron/d4fd5dd9ca26065d577cf5e9b3262c5d?reference=10,2012.0
167,279,1157,Mirtazapine,CN1CCN2C3=C(C=CC=N3)CC3=CC=CC=C3C2C1,Hepatomegaly,Rat,-1.7781512503836436,Repeated,Oral,"FDA approval package document: Pharmacology Review 020415, page:47 PDF 1492k",https://www.pharmapendium.com/browse/fda/Mirtazapine/daf4c7de8d5d70312797cc7f187113e6?reference=47,1995.0
168,280,1158,Modafinil,NC(=O)C[S+]([O-])C(C1=CC=CC=C1)C1=CC=CC=C1,Hepatomegaly,Rat,-1.9520435453393867,Repeated,Oral,"FDA approval package document: Pharmacology Review 020717/S-000 Part 02, page:26 PDF 1034k",https://www.pharmapendium.com/browse/fda/Modafinil/0462b65edc87f475c9a469531c3a6577?reference=26,1997.0
169,282,1173,Monomethyl Fumarate,COC(=O)/C=C/C(=O)O,Hepatomegaly,Rat,-1.3010299956639813,Repeated,Oral,"FDA approval package document: Pharmacology Review 210296/S-000, page:11 PDF 3988k",https://www.pharmapendium.com/browse/fda/Monomethyl Fumarate/9f3241670d6c72beab35d59cf5b64fca?reference=11,2018.0
170,283,1174,Moricizine Hydrochloride,CCOC(=O)NC1=CC=C2SC3=C(C=CC=C3)N(C(=O)CCN3CCOCC3)C2=C1,Hepatomegaly,Rat,-1.6532125137753435,Repeated,Oral,"FDA approval package document: Approval Package 019753 Part 09, page:6 PDF 5140k",https://www.pharmapendium.com/browse/fda/Moricizine Hydrochloride/4e527fce942384adaad7e35e718dffea?reference=6,1990.0
171,284,1176,Moxidectin,CON=C1CC2(CC3CC(C/C=C(\C)CC(C)/C=C/C=C4\COC5C(O)C(C)=CC(C(=O)O3)C45O)O2)OC(/C(C)=C/C(C)C)C1C,Hepatomegaly,Rat,-1.3617278360175928,Repeated,Oral,"FDA approval package document: Pharmacology Review 210867/S-000 Part 04, page:11 PDF 5545k",https://www.pharmapendium.com/browse/fda/Moxidectin/03835837ede2d71152133ba4bcb974b0?reference=11,2018.0
172,286,1179,Mupirocin,CC(=CC(=O)OCCCCCCCCC(=O)O)CC1OCC(CC2OC2C(C)C(C)O)C(O)C1O,Hepatomegaly,Rat,-2.0,Repeated,Subcutaneous,"FDA approval package document: Approval Package 050591 Part 03, page:7 PDF 1048k",https://www.pharmapendium.com/browse/fda/Mupirocin/c16fd32ee0d53a3199d26071e1442070?reference=7,1986.0
173,287,1180,Naftifine Hydrochloride,CN(C/C=C/C1=CC=CC=C1)CC1=CC=CC2=CC=CC=C12,Hepatomegaly,Rat,-2.2604121447557173,Repeated,Oral,"FDA approval package document: Approval Package 019356 Part 02, page:9 PDF 2375k",https://www.pharmapendium.com/browse/fda/Naftifine Hydrochloride/ea179fbdcc1ef2e257f616baaf46cc53?reference=9,1985.0
174,288,1187,Naldemedine Tosylate,CC(C)(NC(=O)C1CC2(O)C3CC4=CC=C(O)C5=C4C2(CCN3CC2CC2)C(O5)C1=O)C1=NC(C2=CC=CC=C2)=NO1,Hepatomegaly,Mouse,-2.7634279935629373,Repeated,Oral,"FDA approval package document: Pharmacology Review 208854/S-000, page:87 PDF 42875k",https://www.pharmapendium.com/browse/fda/Naldemedine Tosylate/cb48888bdb0096eab9489661c298432d?reference=87,2016.0
175,289,1192,Naloxegol Oxalate,C=CCN1CCC23C4=C5C=CC(O)=C4OC2C(OCCOCCOCCOCCOCCOCCOCCOC)CCC3(O)C1C5,Hepatomegaly,Rat,-2.505149978319906,Repeated,Oral,"FDA approval package document: Pharmacology Review 204760/S-000, page:85 PDF 33475k",https://www.pharmapendium.com/browse/fda/Naloxegol Oxalate/170cfe085c4dee733a6c9749a490c3d8?reference=85,2009.0
176,290,1202,Nefopam,CN1CCOC(C2=CC=CC=C2)C2=CC=CC=C2C1,Hepatomegaly,Rat,-1.6812412373755872,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Toxicology and Applied Pharmacology 36,301,1976   ---   DOI:10.1016/0041-008X(76)90009-0   ISSN:0041-008X   JOURNAL:Toxicology and Applied Pharmacology   PAGES:301   VOLUME:36",http://dx.doi.org/10.1016/0041-008X(76)90009-0,1976.0
177,292,1204,Nevirapine,CC1=CC=NC2=C1NC(=O)C1=C(N=CC=C1)N2C1CC1,Hepatomegaly,Rat,-1.7817553746524688,Repeated,Oral,"FDA approval package document: Pharmacology Review 020636 Part 01, page:25 PDF 2707k",https://www.pharmapendium.com/browse/fda/Nevirapine/70bf8bbe576bb560a2e52f27bcd250cf?reference=25,1996.0
178,293,1215,Nicardipine Hydrochloride,COC(=O)C1=C(C)N=C(C)C(C(=O)OCCN(C)CC2=CC=CC=C2)C1C1=CC([N+](=O)[O-])=CC=C1,Hepatomegaly,Rat,-1.6989700043360187,Repeated,Oral,"FDA approval package document: Approval Package 019488 Part 04, page:40 PDF 4302k",https://www.pharmapendium.com/browse/fda/Nicardipine Hydrochloride/7764fec8acb1acaaf49c068a6087901e?reference=40,1988.0
179,294,1217,Nifurtimox,CC1CS(=O)(=O)CCN1/N=C/C1=CC=C([N+](=O)[O-])O1,Hepatomegaly,Rat,-2.0,Repeated,Oral,"FDA approval package document: Approval Package 213464/S-000 Part 03, page:4 PDF 560k",https://www.pharmapendium.com/browse/fda/Nifurtimox/16aef1b3829fd18b40e97ebbbb856c36?reference=4,2020.0
180,297,1222,Nitroglycerin,O=[N+]([O-])OCC(CO[N+](=O)[O-])O[N+](=O)[O-],Hepatomegaly,Rat,-2.587336734507256,Repeated,Oral,"FDA approval package document: Pharmacology Review 021359/S-000, page:88 PDF 8968k",https://www.pharmapendium.com/browse/fda/Nitroglycerin/bf82c8bde9897de9094f6c6a1715d523?reference=88,2010.0
181,299,1226,Obeticholic Acid,CCC1C(O)C2C3CCC(C(C)CCC(=O)O)C3(C)CCC2C2(C)CCC(O)CC12,Hepatomegaly,Mouse,-1.9057958803678683,Repeated,Oral,"FDA approval package document: Pharmacology Review 207999/S-000 Part 03, page:27 PDF 13571k",https://www.pharmapendium.com/browse/fda/Obeticholic Acid/a2a2a577ec5b639dc211430b2c08567e?reference=27,2016.0
182,300,1236,Olopatadine Hydrochloride,CN(C)CC/C=C1/C2=CC=CC=C2COC2=CC=C(CC(=O)O)C=C12,Hepatomegaly,Rat,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Pharmacology Review 021861/S-000 Part 03, page:70 PDF 7519k",https://www.pharmapendium.com/browse/fda/Olopatadine Hydrochloride/e5ba2ffbfb9892a3248b3e0faec4578c?reference=70,2008.0
183,302,1238,Oseltamivir Phosphate,CCOC(=O)C1=CC(OC(CC)CC)C(NC(C)=O)C(N)C1,Hepatomegaly,Rat,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Pharmacology Review 021087/S-000 Part 01, page:12 PDF 1495k",https://www.pharmapendium.com/browse/fda/Oseltamivir Phosphate/014dd98a6b5e4cd40ebc635811d5e4fd?reference=12,1999.0
184,305,1256,Oxcarbazepine,NC(=O)N1C2=CC=CC=C2CC(=O)C2=CC=CC=C21,Hepatomegaly,Rat,-2.5309873556067504,Repeated,Oral,"FDA approval package document: Pharmacology Review 021014, page:21 PDF 3120k",https://www.pharmapendium.com/browse/fda/Oxcarbazepine/026ef210a8d173853cf1c6130530ea7e?reference=21,1999.0
185,306,1270,Ozanimod Hydrochloride,CC(C)OC1=C(C#N)C=C(C2=NC(C3=C4CCC(NCCO)C4=CC=C3)=NO2)C=C1,Hepatomegaly,Mouse,-1.6434526764861874,Repeated,Oral,"FDA approval package document: Pharmacology Review 209899/S-000, page:67 PDF 19004k",https://www.pharmapendium.com/browse/fda/Ozanimod Hydrochloride/a736fe86a523a011de6082eb570d5ce6?reference=67,2020.0
186,308,1277,Palonosetron Hydrochloride,O=C1C2=CC=CC3=C2C(CCC3)CN1C1CN2CCC1CC2,Hepatomegaly,Rat,-2.255272505103306,Repeated,Oral,"FDA approval package document: Pharmacology Review 021372/S-000 Part 02, page:19 PDF 2187k",https://www.pharmapendium.com/browse/fda/Palonosetron Hydrochloride/856d31376b9f74b8932550720df0aa87?reference=19,2003.0
187,310,1295,Paricalcitol,CC(/C=C/C(C)C(C)(C)O)C1CCC2/C(=C/C=C3CC(O)CC(O)C3)CCCC21C,Hepatomegaly,Rat,-6.477121254719663,Repeated,Intravenous,"FDA approval package document: Pharmacology Review 020819/S-000 Part 03, page:14 PDF 866k",https://www.pharmapendium.com/browse/fda/Paricalcitol/084a1822c5c4468ff3413047c42f3989?reference=14,1998.0
188,312,1303,Penciclovir Sodium,NC1=NC(=O)C2=C(N1)N(CCC(CO)CO)C=N2,Hepatomegaly,Rat,-1.9852767431792937,Repeated,Intravenous,"FDA approval package document: Pharmacology Review 020629 Part 01, page:22 PDF 2136k",https://www.pharmapendium.com/browse/fda/Penciclovir Sodium/8bf55ce435a5567b2844e7e0fa6f82fe?reference=22,1995.0
189,313,1306,Peramivir,CCC(CC)C(NC(C)=O)C1C(N=C(N)N)CC(C(=O)O)C1O,Hepatomegaly,Rat,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Pharmacology Review 206426/S-000, page:91 PDF 16739k",https://www.pharmapendium.com/browse/fda/Peramivir/2e265b60dcbb27a240353dc075b92ddd?reference=91,2014.0
190,314,1307,Perampanel,N#CC1=CC=CC=C1C1=CC(C2=NC=CC=C2)=CN(C2=CC=CC=C2)C1=O,Hepatomegaly,Mouse,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Pharmacology Review 202834/S-000 Part 07, page:8 PDF 2405k",https://www.pharmapendium.com/browse/fda/Perampanel/c579050cd85a73c52827e4eac0cc7489?reference=8,2012.0
191,316,1311,Pergolide Mesylate,CCCN1CC(CSC)CC2C3=C4C(=CNC4=CC=C3)CC21,Hepatomegaly,Mouse,-0.7781512503836436,Repeated,Oral,"FDA approval package document: Approval Package 019385 Part 02, page:44 PDF 6033k",https://www.pharmapendium.com/browse/fda/Pergolide Mesylate/f9d216f876775f3890aad904f920a7db?reference=44,1988.0
192,317,1312,Perindopril Erbumine,CCCC(NC(C)C(=O)N1C(C(=O)O)CC2CCCCC21)C(=O)OCC,Hepatomegaly,Mouse,-0.3010299956639812,Repeated,Oral,"FDA approval package document: Pharmacology Review 020184 Part 03, page:30 PDF 2062k",https://www.pharmapendium.com/browse/fda/Perindopril Erbumine/50bd5c0bca23e5db08e0617e257c647d?reference=30,1993.0
193,320,1319,Phenobarbital,CCC1(C2=CC=CC=C2)C(=O)NC(=O)NC1=O,Hepatomegaly,Rat,-0.5440680443502757,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Journal of Toxicological Sciences 33,307,2008   ---   DOI:10.2131/jts.33.307   ISSN:0388-1350   JOURNAL:Journal of Toxicological Sciences   PAGES:307   VOLUME:33",http://dx.doi.org/10.2131/jts.33.307,2008.0
194,321,1326,Phenytoin,O=C1NC(=O)C(C2=CC=CC=C2)(C2=CC=CC=C2)N1,Hepatomegaly,Rat,-1.1139433523068367,Repeated,Intragastric,"Reference from PharmaPendium Published Toxicity: 365835303   ---   DOI:10.1002/bdrb.21022   ISSN:1542-9733   JOURNAL:Birth Defects Research. Part B, Developmental and Reproductive Toxicology   PAGES:337   VOLUME:95",http://dx.doi.org/10.1002/bdrb.21022,2012.0
195,324,1335,Pinacidil,CC(N=C(N=C1C=CNC=C1)NC#N)C(C)(C)C,Hepatomegaly,Rat,-1.130333768495006,Repeated,Oral,"FDA approval package document: Approval Package 019456 Part 01, page:76 PDF 8506k",https://www.pharmapendium.com/browse/fda/Pinacidil/a440d3452eb571b35c22e293cd0f02d2?reference=76,1989.0
196,325,1340,Pindolol,CC(C)NCC(O)COC1=CC=CC2=C1C=CN2,Hepatomegaly,Rat,-1.8195439355418688,Repeated,Oral,"FDA approval package document: Approval Package 018285/S-027 Part 03, page:33 PDF 7358k",https://www.pharmapendium.com/browse/fda/Pindolol/093f84fb76e31f30fe5995137e369dfe?reference=33,1982.0
197,326,1341,Pioglitazone Hydrochloride,CCC1=CN=C(CCOC2=CC=C(CC3=C(O)NC(=O)S3)C=C2)C=C1,Hepatomegaly,Mouse,-1.64738297011462,Repeated,Oral,"FDA approval package document: Pharmacology Review 021073/S-000 Part 02, page:2 PDF 745k",https://www.pharmapendium.com/browse/fda/Pioglitazone Hydrochloride/1986863bd8c3ff638f6b4e553adab37b?reference=2,1999.0
198,327,1347,Piperacillin Sodium,CCN1CCN(C(=O)NC(C(=O)NC2C(=O)N3C2SC(C)(C)C3C(=O)O)C2=CC=CC=C2)C(=O)C1=O,Hepatomegaly,Rat,-3.0,Repeated,Intraperitoneal,"FDA approval package document: Approval Package 050545 Part 03, page:49 PDF 5811k",https://www.pharmapendium.com/browse/fda/Piperacillin Sodium/8e9d225de2a4b238e30fda2f67354300?reference=49,1981.0
199,328,1348,Pirfenidone,CC1=CN(C2=CC=CC=C2)C(=O)C=C1,Hepatomegaly,Rat,-2.98838552153539,Repeated,Oral,"FDA approval package document: Pharmacology Review 022535/S-000 Part 09, page:44 PDF 6836k",https://www.pharmapendium.com/browse/fda/Pirfenidone/86762338ed5d64a5972433c703fdd84b?reference=44,2009.0
200,329,1367,Piroxicam,CN1C(C(=O)NC2=NC=CC=C2)C(=O)C2=CC=CC=C2S1(=O)=O,Hepatomegaly,Rat,-0.0,Repeated,Oral,"FDA approval package document: Approval Package 018147 Part 03, page:42 PDF 6016k",https://www.pharmapendium.com/browse/fda/Piroxicam/c6d6cac31f90d6098fac743ac629feaf?reference=42,1980.0
201,332,1390,Plerixafor,C1=CC(CN2CCCNCCNCCCNCC2)=CC=C1CN1CCCNCCNCCCNCC1,Hepatomegaly,Rat,-1.2174839442139065,Repeated,Subcutaneous,"EMA approval document: Assessment Report EMA/243012/2019; EMEA/H/C/001030/II/0034, page:13 PDF 2135k",https://www.pharmapendium.com/browse/ema/Plerixafor/d79fc7ad591cb5368ee43e3ced04cf6d?reference=13,2019.0
202,334,1393,Prasterone,CC12CCC3C(CC=C4CC(O)CCC43C)C1CCC2=O,Hepatomegaly,Rat,-2.0,Repeated,Oral,"FDA approval package document: Pharmacology Review 208470/S-000, page:14 PDF 2301k",https://www.pharmapendium.com/browse/fda/Prasterone/6366e5790f6ad245e761ad4da8407800?reference=14,2016.0
203,336,1405,Pravastatin Sodium,CCC(C)C(=O)OC1CC(O)C=C2C=CC(C)C(CCC(O)CC(O)CC(=O)O)C21,Hepatomegaly,Rat,-1.9892520064667776,Repeated,Oral,"FDA approval package document: Approval Package 019898/S-003, S-004, S-005, S-006, S-007, S-008, S-009, S-010, S-011, S-013, S-015, S-017, S-020 Part 04, page:2 PDF 1182k",https://www.pharmapendium.com/browse/fda/Pravastatin Sodium/ccd6f2607f9ec13cfe9dceac3d2b0dec?reference=2,1991.0
204,338,1415,Prednicarbate,CCOC(=O)OC1(C(=O)COC(=O)CC)CCC2C3CC=C4CC(=O)C=CC4(C)C3C(O)CC21C,Hepatomegaly,Rabbit,-0.0,Repeated,Skin,"FDA approval package document: Approval Package 020279 Part 02, page:30 PDF 6131k",https://www.pharmapendium.com/browse/fda/Prednicarbate/3000ce24a1423ae6e238bbc8a901ff46?reference=30,1993.0
205,340,1419,Quetiapine Fumarate,OCCOCCN1CCN(C2=NC3=CC=CC=C3SC3=CC=CC=C23)CC1,Hepatomegaly,Mouse,-2.2144362511319007,Repeated,Oral,"FDA approval package document: Pharmacology Review 020639/S-000 Part 02, page:56 PDF 2706k",https://www.pharmapendium.com/browse/fda/Quetiapine Fumarate/0ac2eb7e5d02a8b435545a6136c45d96?reference=56,1997.0
206,341,1447,Rabeprazole Sodium,COCCCOC1=C(C)C(C[S+]([O-])C2=NC3=C(C=CC=C3)N2)=NC=C1,Hepatomegaly,Rat,-1.6763887345811752,Repeated,Oral,"FDA approval package document: Pharmacology Review 020973 Part 01, page:49 PDF 2927k",https://www.pharmapendium.com/browse/fda/Rabeprazole Sodium/c4881415da633564c019c67dcd3a74ee?reference=49,1998.0
207,342,1480,Raloxifene Hydrochloride,O=C(C1=CC=C(OCCN2CCCCC2)C=C1)C1=C(C2=CC=C(O)C=C2)SC2=C1C=CC(O)=C2,Hepatomegaly,Mouse,-2.049218022670181,Repeated,Oral,"FDA approval package document: Pharmacology Review 020815/S-000, page:110 PDF 3294k",https://www.pharmapendium.com/browse/fda/Raloxifene Hydrochloride/33193c4c7ea19bc5eb1ab8dde453c83a?reference=110,1997.0
208,343,1490,Ramelteon,CCC(=O)NCCC1CCC2=CC=C3OCCC3=C21,Hepatomegaly,Mouse,-2.2218487496163566,Repeated,Oral,"EMA approval document: Withdrawal Public Statement EMEA/CHMP/551287/2008, page:13 PDF 834k",https://www.pharmapendium.com/browse/ema/Ramelteon/5841c3e44aad8adfee1364233eb892ad?reference=13,2008.0
209,344,1493,Ramipril,CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N1C(C(=O)O)CC2CCCC21,Hepatomegaly,Rat,-1.3979400086720375,Repeated,Oral,"FDA approval package document: Approval Package 019901/S-013, S-014, S-008, S-009, S-010, S-014, S-011 Part 01, page:52 PDF 3405k",https://www.pharmapendium.com/browse/fda/Ramipril/47610487020f84b20130d67305849a28?reference=52,1991.0
210,345,1494,Ranitidine Hydrochloride,CN=C(C[N+](=O)[O-])NCCSCC1=CC=C(CN(C)C)O1,Hepatomegaly,Rat,-1.484299839346786,Repeated,Oral,Reference from PharmaPendium Published Toxicity: Ranitidin2   ---   JOURNAL:Journal of Toxicological Sciences   PAGES:25   VOLUME:8,,1983.0
211,346,1496,Ranolazine,COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC2=C(C)C=CC=C2C)CC1,Hepatomegaly,Rat,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Pharmacology Review 021526/S-000 Part 03, page:63 PDF 5727k",https://www.pharmapendium.com/browse/fda/Ranolazine/74d38a47948db80bf425451eab34b279?reference=63,2006.0
212,347,1503,Rasagiline Mesylate,C#CCNC1CCC2=CC=CC=C21,Hepatomegaly,Mouse,-1.2041199826559248,Repeated,Oral,"FDA approval package document: Pharmacology Review 021641/S-000 Part 02, page:38 PDF 3944k",https://www.pharmapendium.com/browse/fda/Rasagiline Mesylate/023eb7e29544e727a5e4fed62d4747ff?reference=38,2006.0
213,349,1511,Repaglinide,CCOC1=CC(CC(=O)NC(CC(C)C)C2=CC=CC=C2N2CCCCC2)=CC=C1C(=O)O,Hepatomegaly,Rat,-1.8293037728310249,Repeated,Oral,"FDA approval package document: Pharmacology Review 020741, page:19 PDF 1205k",https://www.pharmapendium.com/browse/fda/Repaglinide/4309f96feb865f95167bc205d82bf04b?reference=19,1997.0
214,350,1513,Resorcinol,OC1=CC(O)=CC=C1,Hepatomegaly,Rat,-1.1139433523068367,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Regulatory Toxicology and Pharmacology 36,198,2002   ---   DOI:10.1006/RTPH.2002.1585   ISSN:0273-2300   JOURNAL:Regulatory Toxicology and Pharmacology   PAGES:198   VOLUME:36",http://dx.doi.org/10.1006/RTPH.2002.1585,2002.0
215,351,1514,Ribavirin,NC(=O)C1=NN(C2OC(CO)C(O)C2O)C=N1,Hepatomegaly,Rat,-1.8016323462331665,Repeated,Oral,"FDA approval package document: Pharmacology Review 020903/S-000 Part 02, page:29 PDF 1570k",https://www.pharmapendium.com/browse/fda/Ribavirin/d510e8bf3bd7f7307a1d2a36cad09c74?reference=29,1998.0
216,352,1520,Ribociclib Succinate,CN(C)C(=O)C1=CC2=C(N=C(NC3=CC=C(N4CCNCC4)C=N3)N=C2)N1C1CCCC1,Hepatomegaly,Rat,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Approval Package 209092/S-000 Part 01, page:46 PDF 1644k",https://www.pharmapendium.com/browse/fda/Ribociclib Succinate/99aa51d42e1c46b54eea97f558d33dc2?reference=46,2016.0
217,353,1521,Rifabutin,COC1/C=C/OC2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)C(C)=CC=CC(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C1C)C1=NC3(CCN(CC(C)C)CC3)N=C12,Hepatomegaly,Rat,-1.6821450763738317,Repeated,Oral,"FDA approval package document: Pharmacology Review 050689, page:11 PDF 2343k",https://www.pharmapendium.com/browse/fda/Rifabutin/8482c5f11425fc4dae4408390a2a35cf?reference=11,1992.0
218,354,1532,Rifampin,COC1/C=C/OC2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)C(C)=CC=CC(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C1C)C(C=NN1CCN(C)CC1)=C2O,Hepatomegaly,Rat,-2.246744709723841,Repeated,Oral,"FDA approval package document: Approval Package 050429, page:45 PDF 4018k",https://www.pharmapendium.com/browse/fda/Rifampin/4c395f8c75dbc0cabc0e90e4b0ff0d05?reference=45,1971.0
219,355,1536,Rifapentine,COC1/C=C/OC2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)C(C)=CC=CC(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C1C)C(C=NN1CCN(C3CCCC3)CC1)=C2O,Hepatomegaly,Rat,-1.619788758288394,Repeated,Oral,"FDA approval package document: Approval Package 021024/S-000 Part 03, page:25 PDF 1576k",https://www.pharmapendium.com/browse/fda/Rifapentine/3571ba2cb11af6b710e653c49818811c?reference=25,1998.0
220,356,1539,Rifaximin,COC1/C=C/OC2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)C(C)=CC=CC(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C1C)C1=C2N=C2C=C(C)C=CN21,Hepatomegaly,Rat,-1.9208187539523751,Repeated,Oral,"FDA approval package document: Pharmacology Review 021361/S-000, page:49 PDF 1768k",https://www.pharmapendium.com/browse/fda/Rifaximin/0dcfa65a09adad88864788784777aad3?reference=49,2003.0
221,357,1542,Rilpivirine Hydrochloride,CC1=CC(C=CC#N)=CC(C)=C1NC1=CC=NC(NC2=CC=C(C#N)C=C2)=N1,Hepatomegaly,Rat,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Pharmacology Review 202022/S-000 Part 02, page:9 PDF 1062k",https://www.pharmapendium.com/browse/fda/Rilpivirine Hydrochloride/c3ce45a25c02c2155610f40b8001efa7?reference=9,2010.0
222,360,1554,Rimexolone,CCC(=O)C1(C)C(C)CC2C3CC=C4CC(=O)C=CC4(C)C3C(O)CC21C,Hepatomegaly,Rat,-1.4393326938302626,Repeated,Subcutaneous,"FDA approval package document: Pharmacology Review 020474, page:7 PDF 1030k",https://www.pharmapendium.com/browse/fda/Rimexolone/21fb7023b21e4586d41358ccab6da507?reference=7,1994.0
223,363,1564,Risdiplam,CC1=CN2N=C(C3=CC(=O)N4C=C(N5CCNC6(CC6)C5)C=CC4=N3)C=C(C)C2=N1,Hepatomegaly,Rat,-0.9542425094393248,Repeated,Oral,"FDA approval package document: Pharmacology Review 213535/S-000, page:27 PDF 14128k",https://www.pharmapendium.com/browse/fda/Risdiplam/0f5247efaeda7b41fddc8aa3b27c40a3?reference=27,2020.0
224,365,1573,Ritodrine Hydrochloride,CC(NCCC1=CC=C(O)C=C1)C(O)C1=CC=C(O)C=C1,Hepatomegaly,Rat,-1.877946951629188,Repeated,Intravenous,"FDA approval package document: Approval Package 018280 Part 02, page:50 PDF 4970k",https://www.pharmapendium.com/browse/fda/Ritodrine Hydrochloride/f505b293543b2ba267d2cab9bb18dd06?reference=50,1980.0
225,366,1575,Ritonavir,CC(C)C1=NC(CN(C)C(=O)NC(C(=O)NC(CC2=CC=CC=C2)CC(O)C(CC2=CC=CC=C2)NC(=O)OCC2=CN=CS2)C(C)C)=CS1,Hepatomegaly,Rat,-1.6812412373755872,Repeated,Oral,"FDA approval package document: Pharmacology Review 020659, page:31 PDF 2500k",https://www.pharmapendium.com/browse/fda/Ritonavir/73d0c1aae62a1c01de24d981e01437d9?reference=31,1995.0
226,368,1582,Rizatriptan Benzoate,CN(C)CCC1=CNC2=C1C=C(CN1C=NC=N1)C=C2,Hepatomegaly,Rat,-2.7958800173440754,Repeated,Oral,"FDA approval package document: Pharmacology Review 020864 Part 02, page:30 PDF 1783k",https://www.pharmapendium.com/browse/fda/Rizatriptan Benzoate/267bc014cf6b43cd4c454e846e7cd932?reference=30,1998.0
227,369,1586,Rofecoxib,CS(=O)(=O)C1=CC=C(C2=COC(O)=C2C2=CC=CC=C2)C=C1,Hepatomegaly,Rat,-2.3082085802911045,Repeated,Oral,"FDA approval package document: Pharmacology Review 021042/S-000; 021052/S-000 Part 05, page:13 PDF 755k",https://www.pharmapendium.com/browse/fda/Rofecoxib/a47caaa4224e9f551ed9bc237244444d?reference=13,1998.0
228,372,1613,Ropinirole Hydrochloride,CCCN(CCC)CCC1=CC=CC2=C1C=C(O)N2,Hepatomegaly,Rat,-1.5006023505691857,Repeated,Oral,"FDA approval package document: Pharmacology Review 020658/S-000 Part 01, page:90 PDF 2731k",https://www.pharmapendium.com/browse/fda/Ropinirole Hydrochloride/9732ae2712990be4523bb8e429d30617?reference=90,1996.0
229,373,1624,Rosiglitazone Maleate,CN(CCOC1=CC=C(CC2=C(O)NC(=O)S2)C=C1)C1=NC=CC=C1,Hepatomegaly,Rat,-1.6020599913279625,Repeated,Oral,"FDA approval package document: Pharmacology Review 021071/S-000 Part 02, page:47 PDF 1207k",https://www.pharmapendium.com/browse/fda/Rosiglitazone Maleate/502d0e89534fcd862f0a037ecfc5e68c?reference=47,1999.0
230,377,1678,Sapropterin Dihydrochloride,CC(O)C(O)C1CNC2=C(N1)C(=O)N=C(N)N2,Hepatomegaly,Rat,-2.0910804693473324,Repeated,Oral,"FDA approval package document: Pharmacology Review 022181/S-000 Part 02, page:25 PDF 7425k",https://www.pharmapendium.com/browse/fda/Sapropterin Dihydrochloride/f138a0099e2946da8eeecd70337a238d?reference=25,2007.0
231,378,1681,Saxagliptin Hydrochloride,N#CC1CC2CC2N1C(=O)C(N)C12CC3CC(CC(O)(C3)C1)C2,Hepatomegaly,Mouse,-2.322219294733919,Repeated,Oral,"FDA approval package document: Pharmacology Review 022350/S-000 Part 01, page:25 PDF 4836k",https://www.pharmapendium.com/browse/fda/Saxagliptin Hydrochloride/864e532affdf974f4b612c87811175bd?reference=25,2009.0
232,379,1685,Secnidazole,CC1=NC=C([N+](=O)[O-])N1CC(C)O,Hepatomegaly,Rat,-3.1760912590556813,Repeated,Oral,"FDA approval package document: Pharmacology Review 209363/S-000 Part 02, page:15 PDF 4578k",https://www.pharmapendium.com/browse/fda/Secnidazole/8c58c18d9abd157647542f6d21d53fe4?reference=15,2017.0
233,380,1687,Selexipag,CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)C1=NC(C2=CC=CC=C2)=C(C2=CC=CC=C2)N=C1,Hepatomegaly,Rat,-1.6020599913279625,Repeated,Oral,"FDA approval package document: Pharmacology Review 207947/S-000 Part 02, page:2 PDF 349k",https://www.pharmapendium.com/browse/fda/Selexipag/2bc19f9855ab9e6118fd02e9b93edcb7?reference=2,2010.0
234,382,1695,Sildenafil Citrate,CCCC1=NN(C)C2=C1N=C(C1=CC(S(=O)(=O)N3CCN(C)CC3)=CC=C1OCC)NC2=O,Hepatomegaly,Rat,-2.074404982081093,Repeated,Oral,"FDA approval package document: Pharmacology Review 020895/S-000 Part 02, page:3 PDF 926k",https://www.pharmapendium.com/browse/fda/Sildenafil Citrate/03ba392f7c45f46128aeb8bc469e5138?reference=3,1998.0
235,384,1715,Simvastatin,CCC(C)(C)C(=O)OC1CC(C)C=C2C=CC(C)C(CCC3CC(O)CC(=O)O3)C21,Hepatomegaly,Rat,-1.375663613960885,Repeated,Oral,"FDA approval package document: Approval Package 019766/S-001, S-002, S-003, S-004, S-005, S-006; 019643/S-041, S-007, S-009, S-037, S-010, S-011, S-013, S-021, S-015 Part 03, page:9 PDF 5142k",https://www.pharmapendium.com/browse/fda/Simvastatin/4ac993ac6bc9a9f5555c1ec9ba3e3165?reference=9,1991.0
236,386,1734,Sirolimus,COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(O)C(OC)C2)CC(=O)C(C)=CC(C)C(O)C(OC)C(=O)C(C)CC(C)/C=C/C=C/C=C/1C,Hepatomegaly,Rat,-1.1139433523068367,Repeated,Intravenous,"FDA approval package document: Pharmacology Review 021083/S-000 Part 01, page:11 PDF 1215k",https://www.pharmapendium.com/browse/fda/Sirolimus/980195f263dd06f8861671f1f5ed844c?reference=11,1999.0
237,390,1754,Solifenacin Succinate,O=C(OC1CN2CCC1CC2)N1CCC2=C(C=CC=C2)C1C1=CC=CC=C1,Hepatomegaly,Rat,-1.3010299956639813,Repeated,Oral,"FDA approval package document: Pharmacology Review 021518/S-000, page:51 PDF 4007k",https://www.pharmapendium.com/browse/fda/Solifenacin Succinate/5191e99bbb43f25a1000a00809048e4b?reference=51,2004.0
238,391,1756,Solriamfetol Hydrochloride,NC(=O)OCC(N)CC1=CC=CC=C1,Hepatomegaly,Rat,-2.300305567669649,Repeated,Oral,"FDA approval package document: Pharmacology Review 211230/S-000 Part 02, page:31 PDF 14043k",https://www.pharmapendium.com/browse/fda/Solriamfetol Hydrochloride/c1b80cfec0a2bfa4ca6310ab50d6d823?reference=31,2018.0
239,393,1761,Spinosad,CCC1CCCC(OC2CCC(N(C)C)C(C)O2)C(C)C(=O)C2=CC3C(C=C(C)C4CC(OC5OC(C)C(OC)C(OC)C5OC)CC43)C2CC(=O)O1,Hepatomegaly,Rat,-0.7781512503836436,Repeated,Oral,"FDA approval package document: Administrative documents 022408/S-000, page:40 PDF 978k",https://www.pharmapendium.com/browse/fda/Spinosad/88344571c93317c8986333189d3c909f?reference=40,2011.0
240,394,1763,Spironolactone,CC(=O)SC1C=C2CC(=O)CCC2(C)C2CCC3(C)C(CCC34CCC(=O)O4)C12,Hepatomegaly,Rat,-0.3010299956639812,Repeated,Unreported,"Reference from PharmaPendium Published Toxicity: Toxicology and Applied Pharmacology 98,263,1989   ---   DOI:10.1016/0041-008X(89)90231-7   ISSN:0041-008X   JOURNAL:Toxicology and Applied Pharmacology   PAGES:263   VOLUME:98",http://dx.doi.org/10.1016/0041-008X(89)90231-7,1989.0
241,395,1764,Stavudine,CC1=CN(C2C=CC(CO)O2)C(=O)NC1=O,Hepatomegaly,Rat,-2.912430013246087,Repeated,Oral,"FDA approval package document: Pharmacology Review 020412, page:13 PDF 2568k",https://www.pharmapendium.com/browse/fda/Stavudine/a19d81d9163ac58f34061720ec61d707?reference=13,1994.0
242,396,1790,Stiripentol,CC(C)(C)C(O)/C=C/C1=CC=C2OCOC2=C1,Hepatomegaly,Mouse,-2.672097857935717,Repeated,Oral,"EMA approval document: Scientific Discussion, page:9 PDF 626k",https://www.pharmapendium.com/browse/ema/Stiripentol/8b3c3cd899e580b814c7a8d81a662714?reference=9,2007.0
243,397,1799,Sugammadex Sodium,O=C(O)CCSCC1OC2OC3C(CSCCC(=O)O)OC(OC4C(CSCCC(=O)O)OC(OC5C(CSCCC(=O)O)OC(OC6C(CSCCC(=O)O)OC(OC7C(CSCCC(=O)O)OC(OC8C(CSCCC(=O)O)OC(OC9C(CSCCC(=O)O)OC(OC1C(O)C2O)C(O)C9O)C(O)C8O)C(O)C7O)C(O)C6O)C(O)C5O)C(O)C4O)C(O)C3O,Hepatomegaly,Rat,-1.869231719730976,Repeated,Multiple,"FDA approval package document: Pharmacology Review 022225/S-000 Part 05, page:122 PDF 39696k",https://www.pharmapendium.com/browse/fda/Sugammadex Sodium/455333aa23398803214d41dd6adbd5b0?reference=122,2008.0
244,399,1802,Sumatriptan Succinate,CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1,Hepatomegaly,Rat,-1.916453948549925,Repeated,Oral,"FDA approval package document: Approval Package 020132/S-003 Part 07, page:72 PDF 8055k",https://www.pharmapendium.com/browse/fda/Sumatriptan Succinate/18e6ca7d448a6382657b7aaf5d1b4ec1?reference=72,1995.0
245,402,1820,Tafamidis Meglumine,CNCC(O)C(O)C(O)C(O)CO,Hepatomegaly,Mouse,-1.7883704155653295,Repeated,Oral,"EMA approval document: Assessment Report EMA/729083/2011; EMEA/H/C/002294, page:17 PDF 1372k",https://www.pharmapendium.com/browse/ema/Tafamidis Meglumine/bffae245d15431e18c066148f6a1c732?reference=17,2011.0
246,403,1827,Tamsulosin Hydrochloride,CCOC1=CC=CC=C1OCCNC(C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1,Hepatomegaly,Mouse,-2.00108438129222,Repeated,Oral,"FDA approval package document: Approval Package 020579/S-000, page:192 PDF 8915k",https://www.pharmapendium.com/browse/fda/Tamsulosin Hydrochloride/4d520d656e6071d5a0b8a892b782821d?reference=192,1997.0
247,404,1837,Tapentadol Hydrochloride,CCC(C1=CC(O)=CC=C1)C(C)CN(C)C,Hepatomegaly,Mouse,-2.4167280755373683,Repeated,Oral,"FDA approval package document: Pharmacology Review 022304/S-000 Part 02, page:19 PDF 6376k",https://www.pharmapendium.com/browse/fda/Tapentadol Hydrochloride/0ad47c11902adf65b04e5c9c7b4f4679?reference=19,2008.0
248,405,1856,Tasimelteon,CCC(=O)NCC1CC1C1=C2CCOC2=CC=C1,Hepatomegaly,Rat,-2.18089014193745,Repeated,Oral,"FDA approval package document: Pharmacology Review 205677/S-000 Part 01, page:54 PDF 12454k",https://www.pharmapendium.com/browse/fda/Tasimelteon/28a85b194d85648bbc6e12b04df9080c?reference=54,2014.0
249,406,1869,Tazarotene,CCOC(=O)C1=CN=C(C#CC2=CC3=C(C=C2)SCCC3(C)C)C=C1,Hepatomegaly,Mouse,,Repeated,Skin,"FDA approval package document: Pharmacology Review 020600, page:15 PDF 2348k",https://www.pharmapendium.com/browse/fda/Tazarotene/dd18fcfb2fc4fdb3abe0fe0e62ddb2e6?reference=15,1996.0
250,407,1874,Tazobactam,CC1(CN2C=CN=N2)C(C(=O)O)N2C(=O)CC2S1(=O)=O,Hepatomegaly,Rat,-0.7781512503836436,Repeated,Intraperitoneal,Reference from PharmaPendium Published Toxicity: Tazobactam2   ---   JOURNAL:Journal of Toxicological Sciences   PAGES:155   VOLUME:19,,1994.0
251,410,1877,Telaprevir,CCCC(NC(=O)C1C2CCCC2CN1C(=O)C(NC(=O)C(NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1,Hepatomegaly,Rat,-1.6989700043360187,Repeated,Oral,"FDA approval package document: Pharmacology Review 201917/S-000 Part 02, page:18 PDF 663k",https://www.pharmapendium.com/browse/fda/Telaprevir/994833aaea01c0d494bb266bccda4925?reference=18,2010.0
252,412,1879,Telithromycin,CCC1OC(=O)C(C)C(=O)C(C)C(OC2OC(C)CC(N(C)C)C2O)C(C)(OC)CC(C)C(=O)C(C)C2N(CCCCN3C=NC(C4=CN=CC=C4)=C3)C(=O)OC12C,Hepatomegaly,Rat,-2.170261715394957,Repeated,Oral,"FDA approval package document: Pharmacology Review 021144/S-000 Part 02, page:10 PDF 1529k",https://www.pharmapendium.com/browse/fda/Telithromycin/0bfc9de8593366a0450186cfddfa13b7?reference=10,2001.0
253,414,1885,Temozolomide,CN1N=NC2=C(C(N)=O)N=CN2C1=O,Hepatomegaly,Rat,-0.3010299956639812,Repeated,Oral,"FDA approval package document: Pharmacology Review 021029, page:34 PDF 2222k",https://www.pharmapendium.com/browse/fda/Temozolomide/7691fbb106093e0f25e9ec91b13879d4?reference=34,1999.0
254,415,1886,Terazosin Hydrochloride,COC1=CC2=NC(N3CCN(C(=O)C4CCCO4)CC3)=NC(N)=C2C=C1OC,Hepatomegaly,Rat,-1.7781512503836436,Repeated,Oral,"FDA approval package document: Approval Package 020223/S-006 Part 08, page:55 PDF 5642k",https://www.pharmapendium.com/browse/fda/Terazosin Hydrochloride/a57390ff0df189db423b400d736a11ac?reference=55,1993.0
255,416,1887,Terbinafine Hydrochloride,CN(C/C=C/C#CC(C)(C)C)CC1=C2C=CC=CC2=CC=C1,Hepatomegaly,Rat,-2.2310871205848226,Repeated,Oral,"FDA approval package document: Pharmacology Review 021958/S-000, page:14 PDF 1167k",https://www.pharmapendium.com/browse/fda/Terbinafine Hydrochloride/372fff314c23293ff5deec07f65e2708?reference=14,2006.0
256,418,1893,Teriparatide (rDNA Origin),CCC(C)C(NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(NC(=O)C(N)CO)C(C)C)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCSC)C(=O)NC(CC1=CNC=N1)C(=O)NC(CC(N)=O)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CC1=CNC=N1)C(=O)NC(CC(C)C)C(=O)NC(CC(N)=O)C(=O)NC(CO)C(=O)NC(CCSC)C(=O)NC(CCC(=O)O)C(=O)NC(CCCN=C(N)N)C(=O)NC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=C1C=CC=C2)C(=O)NC(CC(C)C)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(N)=O)C(=O)NC(CC(=O)O)C(=O)NC(C(=O)NC(CC1=CNC=N1)C(=O)NC(CC(N)=O)C(=O)NC(CC1=CC=CC=C1)C(=O)O)C(C)C)C(C)C,Hepatomegaly,Rat,-7.0,Repeated,Subcutaneous,"FDA approval package document: Pharmacology Review 021318/S-000 Part 03, page:3 PDF 1755k",https://www.pharmapendium.com/browse/fda/Teriparatide (rDNA Origin)/d654102b49a3ab292b00b0bebf635577?reference=3,2001.0
257,419,1894,Testosterone,CC12CCC(=O)C=C1CCC1C2CCC2(C)C(O)CCC12,Hepatomegaly,Rabbit,-1.4471580313422192,Repeated,Intranasal,"FDA approval package document: Pharmacology Review 205488/S-000, page:11 PDF 2230k",https://www.pharmapendium.com/browse/fda/Testosterone/621f07b420a52d73fca84f9965b693e5?reference=11,2013.0
258,421,1896,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,Hepatomegaly,Mouse,-2.380211241711606,Repeated,Oral,"EMA approval document: Assessment Report EMEA/176582/2008, page:14 PDF 488k",https://www.pharmapendium.com/browse/ema/Thalidomide/4363f3dba465302791d1295c230f8be4?reference=14,2008.0
259,423,1904,Thiabendazole,C1=CC=C2NC(C3=CSC=N3)=NC2=C1,Hepatomegaly,Mouse,-1.1139433523068367,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Food and Chemical Toxicology 34,709,1996   ---   DOI:10.1016/0278-6915(96)00035-X   ISSN:0278-6915   JOURNAL:Food and Chemical Toxicology   PAGES:709   VOLUME:34",http://dx.doi.org/10.1016/0278-6915(96)00035-X,1996.0
260,424,1905,Tiagabine Hydrochloride,CC1=C(C(=CCCN2CCCC(C(=O)O)C2)C2=C(C)C=CS2)SC=C1,Hepatomegaly,Mouse,-1.870208760597288,Repeated,Oral,"FDA approval package document: Pharmacology Review 020646, page:36 PDF 2890k",https://www.pharmapendium.com/browse/fda/Tiagabine Hydrochloride/09638a18383c82b3e2207f2eb69702f9?reference=36,1996.0
261,427,1942,Tiotropium Bromide,C[N+]1(C)C2CC(OC(=O)C(O)(C3=CC=CS3)C3=CC=CS3)CC1C1OC12,Hepatomegaly,Rat,-0.4259687322722812,Repeated,Inhalation,"FDA approval package document: Pharmacology Review 021395/S-000 Part 04, page:14 PDF 1337k",https://www.pharmapendium.com/browse/fda/Tiotropium Bromide/ef9984eeaae79affeaa10118d395ad2b?reference=14,2002.0
262,429,1974,Tofacitinib Citrate,CC1CCN(C(=O)CC#N)CC1N(C)C1=C2C=CNC2=NC=N1,Hepatomegaly,Rat,-1.7032913781186614,Repeated,Oral,"FDA approval package document: Pharmacology Review 203214/S-000 Part 05, page:32 PDF 5798k",https://www.pharmapendium.com/browse/fda/Tofacitinib Citrate/a47846ed19f8a03f546a50df492b0f7d?reference=32,2012.0
263,430,1979,Tolcapone,CC1=CC=C(C(=O)C2=CC(O)=C(O)C([N+](=O)[O-])=C2)C=C1,Hepatomegaly,Rat,-2.096910013008056,Repeated,Oral,"FDA approval package document: Pharmacology Review 020697 Part 01, page:35 PDF 2455k",https://www.pharmapendium.com/browse/fda/Tolcapone/37b239eeac94199f740066fa985d35c1?reference=35,1996.0
264,431,1981,Tolterodine Tartrate,CC1=CC=C(O)C(C(CCN(C(C)C)C(C)C)C2=CC=CC=C2)=C1,Hepatomegaly,Rat,-1.4913616938342726,Repeated,Oral,"FDA approval package document: Pharmacology Review 020771/S-000 Part 02, page:2 PDF 964k",https://www.pharmapendium.com/browse/fda/Tolterodine Tartrate/0ba6d187f19f93d93445d86d29ff519a?reference=2,1997.0
265,433,1991,Topiramate,CC1(C)OC2COC3(COS(N)(=O)=O)OC(C)(C)OC3C2O1,Hepatomegaly,Rat,-2.6564176536505557,Repeated,Oral,"FDA approval package document: Pharmacology Review 020505/S-000, page:27 PDF 2537k",https://www.pharmapendium.com/browse/fda/Topiramate/91cb6557a8f3ff9a415095008378e376?reference=27,1995.0
266,435,2004,Trabectedin,COC1=C(O)C=C2CCNC3(CSC4C5=C(C6=C(OCO6)C(C)=C5OC(C)=O)C(COC3=O)N3C(O)C5CC6=C(C(O)=C(OC)C(C)=C6)C(C43)N5C)C2=C1,Hepatomegaly,Mouse,-0.3010299956639812,Repeated,Intravenous,"EMA approval document: Scientific Discussion, page:7 PDF 1081k",https://www.pharmapendium.com/browse/ema/Trabectedin/99561900e0bb277dde3f10a108ff162b?reference=7,2007.0
267,436,2005,Treprostinil Diolamine,CCCCCC(O)CCC1C(O)CC2CC3=C(OCC(=O)O)C=CC=C3CC21,Hepatomegaly,Rat,-1.0,Repeated,Oral,"FDA approval package document: Pharmacology Review 203496/S-000 Part 03, page:6 PDF 9686k",https://www.pharmapendium.com/browse/fda/Treprostinil Diolamine/f83e432762117aeadba44bfea378a798?reference=6,2012.0
268,437,2006,Treprostinil Sodium,CCCCCC(O)CCC1C(O)CC2CC3=C(C=CC=C3OCC(=O)O)CC21,Hepatomegaly,Rat,-2.8115750058705933,Repeated,Subcutaneous,"FDA approval package document: Pharmacology Review 021272/S-000 Part 02, page:1 PDF 1377k",https://www.pharmapendium.com/browse/fda/Treprostinil Sodium/950949a598ddf9aaba1a0f474f0c52fc?reference=1,2001.0
269,438,2007,Tretinoin,CC(C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)=CC(=O)O,Hepatomegaly,Rat,-0.6020599913279624,Repeated,Oral,"FDA approval package document: Pharmacology Review 019963, page:19 PDF 729k",https://www.pharmapendium.com/browse/fda/Tretinoin/cf417333aae6a59c41cd6f24dd8d2185?reference=19,1989.0
270,442,2021,Troglitazone,CC1=C(O)C(C)=C2CCC(C)(COC3=CC=C(CC4=C(O)NC(=O)S4)C=C3)OC2=C1C,Hepatomegaly,Rat,-2.5462341061067835,Repeated,Oral,"FDA approval package document: Pharmacology Review 020720, page:28 PDF 1809k",https://www.pharmapendium.com/browse/fda/Troglitazone/026794b7ceed7db0fbb4589a6a4a82fb?reference=28,1997.0
271,443,2030,Troleandomycin,COC1CC(OC2C(C)C(=O)OC(C)C(C)C(OC(C)=O)C(C)C(=O)C3(CO3)CC(C)C(OC3OC(C)CC(N(C)C)C3OC(C)=O)C2C)OC(C)C1OC(C)=O,Hepatomegaly,Rat,-0.4771212547196624,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Toxicology and Applied Pharmacology 119,181,1993   ---   DOI:10.1006/TAAP.1993.1059   ISSN:0041-008X   JOURNAL:Toxicology and Applied Pharmacology   PAGES:181   VOLUME:119",http://dx.doi.org/10.1006/TAAP.1993.1059,1993.0
272,444,2031,Trypan Blue,CC1=C(N=NC2=C(S(=O)(=O)O)C=C3C=C(S(=O)(=O)O)C=C(N)C3=C2O)C=CC(C2=CC=C(N=NC3=C(S(=O)(=O)O)C=C4C=C(S(=O)(=O)O)C=C(N)C4=C3O)C(C)=C2)=C1,Hepatomegaly,Rat,-0.7781512503836436,Repeated,Subcutaneous,Reference from PharmaPendium Published Toxicity: trypan blue28   ---   ISSN:0002-9440   JOURNAL:American Journal of Pathology   PAGES:326   VOLUME:106,,1982.0
273,445,2032,Tucatinib,CC1=CC(NC2=NC=NC3=CC=C(N=C4NC(C)(C)CO4)C=C23)=CC=C1OC1=CC2=NC=NN2C=C1,Hepatomegaly,Rat,-1.1139433523068367,Repeated,Oral,"FDA approval package document: Approval Package 213411/S-000 Part 03, page:18 PDF 716k",https://www.pharmapendium.com/browse/fda/Tucatinib/ef696b946e4eeb2c99883f4f117aef7c?reference=18,2020.0
274,446,2038,Ulipristal Acetate,CC(=O)OC1(C(C)=O)CCC2C3=C(C4=C(CC3)CC(=O)CC4)C(C3=CC=C(N(C)C)C=C3)CC21C,Hepatomegaly,Rat,-1.7781512503836436,Repeated,Oral,"EMA approval document: Assessment Report EMEA/261787/2009, page:14 PDF 776k",https://www.pharmapendium.com/browse/ema/Ulipristal Acetate/f522be49e24b92c271ae6a27a54ffcb9?reference=14,2011.0
275,448,2049,Unoprostone Isopropyl,CCCCCCCC(=O)CCC1C(O)CC(O)C1C/C=C\CCCC(=O)OC(C)C,Hepatomegaly,Rat,-1.0413926851582251,Repeated,Subcutaneous,"FDA approval package document: Pharmacology Review 021214/S-000 Part 02, page:37 PDF 1616k",https://www.pharmapendium.com/browse/fda/Unoprostone Isopropyl/88c03ac84abd0452a210e7aa1e37ca8f?reference=37,2000.0
276,449,2051,Ursodiol,CC(CCC(=O)O)C1CCC2C3C(O)CC4CC(O)CCC4(C)C3CCC12C,Hepatomegaly,Rat,-5.184691430817598,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020675/S-000 Part 01, page:28 PDF 1089k",https://www.pharmapendium.com/browse/fda/Ursodiol/0f442696e8a94f2bab887a2dbd4387fe?reference=28,1996.0
277,450,2055,Valdecoxib,CC1=C(C2=CC=C(S(N)(=O)=O)C=C2)C(C2=CC=CC=C2)=NO1,Hepatomegaly,Mouse,-2.6241101320710367,Repeated,Oral,"FDA approval package document: Pharmacology Review 021341/S-000 Part 01, page:22 PDF 1454k",https://www.pharmapendium.com/browse/fda/Valdecoxib/b9e49f53f6d96c53bfd321b4e774e3fd?reference=22,2001.0
278,451,2061,Valsartan,CCCCC(=O)N(CC1=CC=C(C2=CC=CC=C2C2=NNN=N2)C=C1)C(C(=O)O)C(C)C,Hepatomegaly,Mouse,-1.7781512503836436,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020665, page:16 PDF 1695k",https://www.pharmapendium.com/browse/fda/Valsartan/ccb958da9cca11b7e8c489e3e10871d1?reference=16,1995.0
279,452,2062,Vardenafil Hydrochloride,CCCC1=NC(C)=C2C(=O)NC(C3=C(OCC)C=CC(S(=O)(=O)N4CCN(CC)CC4)=C3)=NN12,Hepatomegaly,Rat,-1.863322860120456,Repeated,Oral,"FDA approval package document: Pharmacology Review 021400/S-000 Part 02, page:30 PDF 1762k",https://www.pharmapendium.com/browse/fda/Vardenafil Hydrochloride/9f7fc57e2117ea49e6618d8ea285ee7e?reference=30,2002.0
280,453,2074,Varenicline Tartrate,C1=CN=C2C=C3C(=CC2=N1)C1CNCC3C1,Hepatomegaly,Rat,-1.4771212547196624,Repeated,Oral,"FDA approval package document: Pharmacology Review 021928/S-000 Part 02, page:35 PDF 5452k",https://www.pharmapendium.com/browse/fda/Varenicline Tartrate/39576e5a6c086fa0cd3135c24d73bf80?reference=35,2006.0
281,455,2077,Vidarabine,NC1=NC=NC2=C1N=CN2C1OC(CO)C(O)C1O,Hepatomegaly,Mouse,-2.8836614351536176,Repeated,Intramuscular,"FDA approval package document: Approval Package 050523, page:8 PDF 6146k",https://www.pharmapendium.com/browse/fda/Vidarabine/2f5df6b2c70ad513d76a070d1f5b0b66?reference=8,1983.0
282,456,2081,Vinorelbine Tartrate,CCC1=CC2CN1CCC1=C(NC3=CC=CC=C13)C(C(=O)OC)(C1=C(OC)C=C3C(=C1)C14CCN5CC=CC(CC)(C(OC(C)=O)C(O)(C(=O)OC)C1N3C)C54)C2,Hepatomegaly,Rat,-0.8750612633917001,Repeated,Intravenous,"FDA approval package document: Pharmacology Review 020388, page:35 PDF 3122k",https://www.pharmapendium.com/browse/fda/Vinorelbine Tartrate/6cd0bc8880d24aeb132a69f2e0221019?reference=35,1993.0
283,457,2085,Voclosporin,C=C/C=C/CC(C)C(O)C1C(=O)NC(CC)C(=O)N(C)CC(=O)N(C)C(CC(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(CC(C)C)C(=O)NC(C)C(=O)NC(C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(C(C)C)C(=O)N1C,Hepatomegaly,Rat,-1.1760912590556811,Repeated,Oral,"FDA approval package document: Approval Package 213716/S-000 Part 22, page:37 PDF 13336k",https://www.pharmapendium.com/browse/fda/Voclosporin/97191c69db999353a94fab09cbed0966?reference=37,2010.0
284,458,2091,Volanesorsen,COCCOC1C(O)C(COP(=O)(S)OC2C(COP(=O)(S)OC3C(COP(=O)(S)OC4C(COP(=O)(S)OC5C(COP(=O)(S)OC6CC(N7C=C(C)C(N)=NC7=O)OC6COP(=O)(S)OC6CC(N7C=NC8=C7N=C(N)NC8=O)OC6COP(=O)(S)OC6CC(N7C=NC8=C7N=CN=C8N)OC6COP(=O)(S)OC6CC(N7C=C(C)C(N)=NC7=O)OC6COP(=O)(S)OC6CC(N7C=C(C)C(N)=NC7=O)OC6COP(=O)(S)OC6CC(N7C=C(C)C(=O)NC7=O)OC6COP(=O)(S)OC6CC(N7C=NC8=C7N=C(N)NC8=O)OC6COP(=O)(S)OC6CC(N7C=C(C)C(=O)NC7=O)OC6COP(=O)(S)OC6CC(N7C=C(C)C(=O)NC7=O)OC6COP(=O)(S)OC6CC(N7C=C(C)C(N)=NC7=O)OC6COP(=O)(S)OC6C(COP(=O)(S)OC7C(COP(=O)(S)OC8C(COP(=O)(S)OC9C(COP(=O)(S)OC%10C(CO)OC(N%11C=NC%12=C%11N=CN=C%12N)C%10OCCOC)OC(N%10C=NC%11=C%10N=C(N)NC%11=O)C9OCCOC)OC(N9C=C(C)C(N)=NC9=O)C8OCCOC)OC(N8C=C(C)C(=O)NC8=O)C7OCCOC)OC(N7C=C(C)C(=O)NC7=O)C6OCCOC)OC(N6C=C(C)C(=O)NC6=O)C5OCCOC)OC(N5C=C(C)C(=O)NC5=O)C4OCCOC)OC(N4C=C(C)C(=O)NC4=O)C3OCCOC)OC(N3C=NC4=C3N=CN=C4N)C2OCCOC)OC1N1C=C(C)C(=O)NC1=O,Hepatomegaly,Mouse,-1.5835765856339494,Repeated,Subcutaneous,"EMA approval document: Public Assessment Report EMA/180717/2019; EMEA/H/C/004538/0000, page:38 PDF 2540k",https://www.pharmapendium.com/browse/ema/Volanesorsen/ffed6226a16c8c31a83ba8bf3f4abd39?reference=38,2019.0
285,460,2100,Vortioxetine Hydrobromide,CC1=CC(C)=C(SC2=CC=CC=C2N2CCNCC2)C=C1,Hepatomegaly,Rat,-1.72153583223476,Repeated,Oral,"FDA approval package document: Pharmacology Review 204447/S-000 Part 01, page:67 PDF 8806k",https://www.pharmapendium.com/browse/fda/Vortioxetine Hydrobromide/e45e9e6167d7c8df7a2d36a610931d77?reference=67,2013.0
286,461,2109,Voxelotor,CC(C)N1N=CC=C1C1=NC=CC=C1COC1=C(C=O)C(O)=CC=C1,Hepatomegaly,Rat,-2.439332693830263,Repeated,Oral,"FDA approval package document: Approval Package 213137/S-000 Part 01, page:10 PDF 890k",https://www.pharmapendium.com/browse/fda/Voxelotor/abdf76fc0dda49f9c92ac8178af4a1ff?reference=10,2019.0
287,462,2114,Zafirlukast,COC1=CC(C(=O)NS(=O)(=O)C2=CC=CC=C2C)=CC=C1CC1=CN(C)C2=C1C=C(NC(=O)OC1CCCC1)C=C2,Hepatomegaly,Rat,-2.7954938061297363,Repeated,Oral,"FDA approval package document: Pharmacology Review 020547, page:11 PDF 1359k",https://www.pharmapendium.com/browse/fda/Zafirlukast/5a90638a48bcb156c85eaee2a579b826?reference=11,1990.0
288,463,2124,Zaleplon,CCN(C(C)=O)C1=CC=CC(C2=CC=NC3=C(C#N)C=NN23)=C1,Hepatomegaly,Mouse,-1.9247714045076303,Repeated,Oral,"FDA approval package document: Pharmacology Review 020859/S-000 Part 05, page:9 PDF 876k",https://www.pharmapendium.com/browse/fda/Zaleplon/a8826d4d5547cc25b00652fd270e2a88?reference=9,
289,464,2147,Zanubrutinib,C=CC(=O)N1CCC(C2CCNC3=C(C(N)=O)C(C4=CC=C(OC5=CC=CC=C5)C=C4)=NN32)CC1,Hepatomegaly,Rat,-1.6989700043360187,Repeated,Oral,"FDA approval package document: Approval Package 213217/S-000 Part 02, page:15 PDF 15322k",https://www.pharmapendium.com/browse/fda/Zanubrutinib/29d03225a4fe0c37218e413611217951?reference=15,2019.0
290,465,2148,Zileuton,CC(C1=CC2=CC=CC=C2S1)N(O)C(N)=O,Hepatomegaly,Mouse,-2.3061918492997684,Repeated,Oral,"FDA approval package document: Pharmacology Review 020471 Part 03, page:5 PDF 973k",https://www.pharmapendium.com/browse/fda/Zileuton/e763bc45684ed2ee3748851e21caa375?reference=5,1993.0
291,468,2222,Zoledronic Acid,O=[PH](=O)(O)C(O)(CN1C=CN=C1)[PH](=O)(=O)O,Hepatomegaly,Rat,-0.6600519383056491,Repeated,Oral,"FDA approval package document: Pharmacology Review 021223/S-000 Part 04, page:41 PDF 1063k",https://www.pharmapendium.com/browse/fda/Zoledronic Acid/3b79e0e78d53102f6d47f9a7bd57c0c0?reference=41,2000.0
292,469,2237,Zolmitriptan,CN(C)CCC1=CNC2=C1C=C(CC1COC(=O)N1)C=C2,Hepatomegaly,Rat,-2.3273589343863303,Repeated,Oral,"FDA approval package document: Pharmacology Review 020768 Part 01, page:32 PDF 2566k",https://www.pharmapendium.com/browse/fda/Zolmitriptan/be5ba3ecf3ddd4fb10637400f32979cf?reference=32,1997.0
293,470,2239,Zonisamide,NS(=O)(=O)CC1=NOC2=CC=CC=C12,Hepatomegaly,Rat,-2.134520365244195,Repeated,Oral,"FDA approval package document: Pharmacology Review 020789, page:12 PDF 1894k",https://www.pharmapendium.com/browse/fda/Zonisamide/516123f418cf0e281d97bcdb9bec0c47?reference=12,1998.0
